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Abstract 
The interaction between Protein A and Immunoglobulin G (IgG) was studied at a variety of 
pH values using a surface plasmon resonance (SPR) device, which provides real time kinetic 
data without labelling or molecular alteration. This study was carried out due to the large 
scale use of Protein A affinity chromatography for the purification of IgG for pharmaceutical 
purposes, and is one of the most costly steps in the purification process. The results produced 
were largely in line with those produced in previous literature with binding remaining strong 
between pH 7.4 and 5.0, although the association rate decreased as pH decreased. Below pH 
5.0, the rate of IgG elution markedly increased, with pH 3.5 showing near full elution 
seconds after the association phase of the SPR interaction finished. Problems were 
encountered with non-specific binding between the SPR sensor chip and IgG occurring under 
a variety of conditions, requiring various remedies. However, no complete interactions were 
successfully carried out under pH 5.0, so the results obtained below this value were obtained 
by binding at pH 7.4 and then elution at the desired pH.  
 
The data showed binding behaviour that was most successfully explained by a three-site 
model, each with a binding ratio of 1:1. The binding ratio is questionable given that Protein A 
and IgG typically bind at a ratio of 1:2 but may be explained by the sites being independent 
of one another and thus no secondary attachment is observed. A variety of models were fitted 
to the data but only two- and three-site models fitted the experimental data, with the three-site 
model being a more accurate and robust fit across pH changes. A multiple site model seems 
intuitively correct given the six different binding sites that Protein A has for interaction with 
IgG. The models produced have potential applications in a larger model of Protein A affinity 
chromatography, although a number of additional factors would need to be taken into 
account, such as mass transfer effects and the IgG concentration gradient.  
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Chapter 1: Introduction 
Monoclonal antibodies, particularly Immunoglobulin G, are used extensively in the treatment 
of a variety of diseases in both humans and animals, including bowel, lung and breast cancer 
as well as Crohn’s disease and rheumatoid arthritis. Monoclonal antibodies can be produced 
in a variety of ways, with mammalian cell culture the most popular current method, while 
transgenic plants and animals showing promise for the future. Regardless of how the mAb is 
produced it is generally expressed at low concentrations and in the presence of a large 
number of impurities. Protein A (or Protein A fragment) affinity chromatography is almost 
universally used as one of the first steps in mAb purification due to its high specificity and 
yields, removing the majority of impurities in a single step. However, Protein A 
chromatography is expensive with the media costing upwards of NZ$10,000 per litre. IgG is 
also highly valuable with production costs exceeding $1000 per gram in some circumstances. 
Given these costs and the benefits that IgG therapeutics possess any improvement on the 
purification is of great value. An unfortunate side-effect of the strong affinity between Protein 
A and IgG is that harsh conditions, usually low pH, are required for elution, which can 
damage IgG. The IgG is highly valuable given due to the high production costs and thus 
minimising the loss of IgG in the process is crucial to decreasing the price of these potentially 
life-saving drugs.  Therefore it is the aim of this research is to better understand the effects of 
pH, and to a lesser extent salt concentration, on the binding between IgG and Protein A.    
 
1.1 Structure and Characteristics of Immunoglobulin G 
IgG is produced both in human and animals by white blood cells and makes up 75% of the 
antibodies in human serum. IgG is a simple antibody in the form of a Y-shape as shown in 
Figure 1.1, with the various different regions labelled. IgG is made up of four polypeptide 
chains, two identical heavy chains of approximately 50 kDa (60 kDa for IgG3) and two 
identical light chains of 25 kDa to make up the full 150 kDa (170 kDa for IgG3) 
structure(11). The chains are held together by disulfide bonds and non-covalent interactions 
(such as hydrogen bonds and electrostatic interactions). The antigen binding site (region 3 in 
Figure 1.1) is altered to fit receptors on pathogenic cells by the immune system. This allows 
IgG to be used to target an almost unlimited variety of diseases, which has resulted in the 
production of IgG grow every year since its potential was first discovered. The Fc region can 
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also be removed (leaving only the Fab fragment) or have other molecules attached to provide 
different therapeutic effects without affecting the binding mechanism between the IgG and 
pathogen. 
 
Figure 1.1: Basic structure of immunoglobulin G. 1) The Fab region. 2) The Fc region (constant region). 
3) The heavy chain (blue). 4) The light chain (green). 5) Antigen binding site. 6) Hinge region.  –S-S- 
indicates the disulfide bonds that hold the sections together. 
There are four human IgG subclasses known as IgG1 to IgG4 and their structures shown are 
in Figure 1.2. They are named based on their abundance in human serum, e.g. IgG1 is the 
most abundant and IgG4 is the least abundant. The Fc (constant) region is 95% similar across 
all subclasses allowing most IgG to be purified by Fc region interactions, such as those that 
occur with Protein A (11). IgG3 shows the greatest structural variation with the heavy chains 
each being 10 kDa larger which affects the Fc region binding, causing IgG3 to have no 
significant interaction with protein A.   
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. 
Figure 1.2: The different subclasses of IgG in humans. 
1.2 Structure and Characteristics of Protein A 
Protein A is a cell wall protein found on the pathogenic bacteria Staphylococcus Aureus. The 
reasons for the strong affinity between IgG and Protein A is that Staphylococcus Aureus 
produces Protein A as a counter-measure against IgG to thwart the immune response against 
the Staphylococcus (12). Protein A is a 42 kDa (13) or 56 kDa (14) consisting of four (13) or 
five (15) repeating regions (known as the A-E domains) that bind to the Fc region of IgG. 
The D domain also shows some limited Fab binding (16) through weak interactions with the 
heavy chain, although this interaction is considerably weaker than the Fc-binding interactions 
(17). The multiple binding sites ensure that regardless of the method of surface 
immobilisation it will always be able to bind IgG.  Protein A shows an extended shape 
containing a number of α-helices (13), shown in Figure 1.3, which allows it to bind two IgG 
molecules when in solution (18, 19), despite being around one-third the size of IgG. The 
repeating units are highly homologous, showing similar amino acid sequences and allowing 
each unit to bind with the Fc region on IgG (20). These units also show multiple binding sites 
for the cell wall of Staphylococcus Aureus as expected.  
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Figure 1.3: Structure of Z-domain an analogue of the B-domain (one of the five domains in protein A) 
used for IgG purification. 
Protein A has a number of other properties that make it a useful tool in affinity 
chromatography. It is stable over a wide range of pH (2-11) and is able to refold after 
treatment with a denaturating agent like guanidine or urea (21). It is easy to produce, either 
via cultures of the native Stapholoccocus Aureus or by recombinant cultures of E. Coli. 
Protein A also holds up well when cleaned with 0.5 M sodium hydroxide, showing only a 
minor loss of activity and no increase in leakage into the eluate (22). This stability ensures 
Protein A’s use in affinity chromatography, because long-term repeated use is an important 
economic consideration when it comes to purification methods, particularly high-cost ones 
like affinity chromatography.          
 
1.3 Surface Plasmon Resonance 
For this research a ProteOn™ XPR36 (Bio-Rad Laboratories, Hercules, CA, USA) protein 
interaction array system was used to measure the interactions between the IgG and Protein A 
in real time without any markers or alteration to the molecules. This system is a surface 
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plasmon resonance (SPR) device that uses polarised light to measure molecule interactions on 
a metallic surface (23, 24), allowing for real time reaction kinetics to be determined with a 
high level of accuracy. The system uses a setup similar to HPLC (making it a good analogue 
for this project) with a stationary phase of surface bound molecules (the ligand) interacting 
with another molecule (the analyte) in a mobile liquid phase. The ligand is bound on a thin 
metallic (usually gold but silver and aluminium can also be used) surface that sits atop a glass 
prism. The light from the device passes through one edge of the prism, before reflecting off 
the metal surface and exiting out the other side of the prism. A diagram of the chip setup and 
operation is shown in Figure 1.4. 
 
Figure 1.4: Schematic of the measuring element of an SPR device. 
 
SPR devices work by emitting the polarised light at an exact angle (shown as θ in Figure 1.4) 
and measuring the reflected beam over a range of angles. The change in the angle of the 
lowest intensity of reflected light is proportional to the change in refractive index, which is 
affected by the amount of molecules within 200 nm of the metallic surface (24). This is 
caused by the SPR phenomena; when light strikes a thin metallic surface some of the energy 
is transferred to the surface, creating a plasmon wave (23). The amount of energy absorbed is 
affected by the conditions on the other side of the metallic surface. The prism is used to 
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increase the wave number of the light and hence the light impulse to generate a greater 
response. This is all carried out via computer allowing for the highest level of precision and 
the ability to take multiple readings per second for extremely accurate data. The output data is 
given as response units (RU) which can be converted into concentration by the following 
equation (25): 
ߛ = ܴ ∗ 10ି଺
ܯܹ
 
where: γ = Surface concentration on chip (mol/m2) 
 R = Response (RU) 
 MW = Molecular weight (g/mol) 
 
The ligand is not directly bound to the metallic layer, as in most cases that would greatly 
reduce the functionality in reactions of the ligand. An alginate, dextran or polyethylene-
glycol layer (26) is generally employed to provide the binding surface for the ligand. The 
ligand is most frequently bound by direct coupling with the polymer layer via amine, 
carbohydrate or thiol coupling. However direct bonding can reduce activity as the binding is 
usually non-specific and can hinder analyte access to reaction sites. A number of indirect 
binding systems exist, including histidine-tag binding that works in the same way as 
immobilised metal affinity chromatography, or using antibodies as a linker molecule to 
ensure the ligand is perfectly positioned, as shown in Figure 1.5. 
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Figure 1.5: Indirect ligand binding via an antibody linker. 
 
SPR is an effective system for measuring molecular interactions for a number of reasons. As 
previously mentioned SPR devices provide real time data, giving a complete picture of how 
the reaction is occurring, unlike ELISA or a simple reaction vessel, where only snapshots of 
the reaction can be taken. The other advantage of the SPR system is that no modification of 
the molecules is required, unlike systems that use fluorescence, which means the interaction 
between the ligand and analyte will match normal reaction conditions as closely as possible. 
The downside of this is that SPR lacks specificity and any molecule that adheres to the 
surface will generate a response. This necessitates careful preparation of samples to ensure as 
little chance of impurities as possible. The alginate layer causes the interactions to inexactly 
replicate surface binding, while also not perfectly replicating free solution binding. However, 
previous studies have found that, within experimental error, SPR methods replicate free 
solution methods (16). The final advantage of SPR is that it can monitor a number of 
interactions at the same time, the XPR36 allows six different ligands to be bound onto their 
own individual channel and six analytes to be passed across at one time hence allowing a 
possible 36 interactions at once. Other commercially available systems have a similar number 
of interaction sites but some go as high as 400 sites (Biacore Flexichip Kinetic Analysis 
system, Little Chalfont, United Kingdom). 
 
Each interaction performed on the SPR follows a specific form made up of three stages, as 
shown in Figure 1.6. The first step is simply to run some buffer over the chip to establish a 
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baseline, which forms the basis for comparison with the remaining steps. In the second stage 
(association/binding stage) the analyte sample is injected across the chip and the interaction 
occurs, with the flow rate and length of injection controlled by the user. The final stage 
(dissociation/elution stage) returns the chip to running buffer for a user-defined amount of 
time. The association and dissociation phases are used to determine the kinetics of the 
interaction. The regeneration and blank steps that are used between interactions follow a 
similar form, with the sample injection between to buffer stages (although they are generally 
equally short).  
 
 
Figure 1.6: The three interaction stages using a SPR. A) Blank (buffer) stage. B) Association/interaction 
stage. C) Dissociation/elution stage. Each curve (“sensorgram”) represents a different analyte 
concentration.  
 
1.4 Protein A Affinity Chromatography   
Protein A and a variety of derivatives are regularly used in affinity chromatography to purify 
IgG. This is evident by the large number of manufacturers and products available, from Bio-
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rad’s UNOsphere SUPrA™ media through Millipore’s Prosep®-Va media to GE’s Mab 
Select Range, all of which use Protein A or a Protein A derivative and sell for upwards of 
NZ$10,000/l. The growing use of monoclonal antibodies (IgG, IgD and IgE) for therapeutic 
purposes has provided a large market for the Protein A media, with at least 23 different mAbs 
currently in use (8) and hundreds in development (27).  
 
Affinity chromatography follows the standard liquid chromatography form, being comprising 
a column filled with a solid stationary phase through which a mobile liquid phase flows (28). 
The stationary phase is made up of multiple beads (usually roughly spherical in shape) upon 
which the ligand is bound. The ligand is selected for its specificity of binding for a desired 
product; in this case the ligand is protein A and the product IgG. Often the beads contain 
pores or channels to increase the amount of surface area for increased ligand binding. The 
beads can be made out of any of a number of materials, often with polymers, agarose and 
glass. The stationary phase can be called the matrix or the medium/media. The basic setup 
and performance of affinity media is shown in Figure 1.7. 
 
 
Figure 1.7: Basic setup and action of an affinity chromatography system.   
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Any liquid chromatography process contains a number of steps for product separation. The 
first step is to equilibrate the column, usually by running a buffer similar or identical to the 
buffer containing the product. The next step is to run the product through for capture onto the 
media. This is followed by washing with the original buffer and then the elution step, where 
the buffer is contains a modifier component to change (pH, conductivity, organic content or 
other properties) using either a step change or a gradient to elute the product(s). Finally a 
cleaning step is performed to remove any remaining product or impurities from the column, 
and this step is usually done with a high conductivity, strong acid or base. 
 
Currently most processes use harsh conditions, with buffers with a pH of 3 or less to elute 
IgG off the Protein A column. This can lead to aggregation and degradation of IgG making it 
useless for therapeutic purposes (29). While this damage can be minimised with good 
operational practices it would be preferable to find a solution that reduces or eliminates the 
damage to the IgG, especially given the significant value of even small amounts of 
therapeutic IgG. The harsh pH is used to ensure the complete elution, because of the 
perceived strength of the interaction between IgG and Protein A and the difficulty of fully 
removing bound IgG that the interaction causes. Determinig whether this level of acidity is 
truly required for elution is the subject of this thesis.  
 
A number of purification alternatives exist to a Protein A column. Protein G and Protein L 
are similar in effect to Protein A, with strong antibody affinity. Protein G is the more similar 
of the two; binding to the Fab and Fc regions of IgG and often used in combination with 
Protein A to enhance overall binding. Native Protein G also binds albumin but this binding is 
usually eliminated in its recombinant forms. Protein A does not bind IgG3, which is one 
reason it is used in combination with Protein G (which does). A combination of non-affinity 
chromatographic techniques can also be used for purification but this is unpopular due to the 
greater number of steps needed to replicate the purification achieved in one Protein A step.  
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1.5 Project Objectives 
The increasing growth of monoclonal antibody therapeutics and their reliance on Protein A 
affinity chromatography as a means of purification makes understanding the interaction 
between IgG and Protein A important to ensure that existing and new drugs are as cheap as 
possible to allow the greatest number of people and animals to benefit from them. While a 
great deal of work has been done on the various binding sites and their mechanisms, there 
seems to be little research examining how the complete molecules interact (specifically their 
association and dissociation constants) and how that interaction is effected by pH changes. 
This project intends to fill that gap by using a SPR device to examine the interactions 
between IgG and Protein A over a range of pH conditions. Other current (unpublished work) 
by Professor Giorgio Carta (University of Virginia) and colleagues shows variation between 
the elution pH of mAbs and that of the elution buffer used, which calls into question 
established methods for elution. IgG is sensitive to low pH and can degrade under normal 
(pH 3) elution conditions causing loss of product. By examining the interaction kinetics over 
a range of pH it is hoped that a more optimal solution can be found that allows elution while 
decreasing or eliminating product degradation. 
 
1.6 Scope and Organisation of Thesis 
 The current knowledge of the interactions between IgG and Protein A as well as their effects 
on wider process considerations are presented in the next chapter. Chapter 3 describes the 
equations and models used for analysing the experimental data and the software programs 
that best utilise them. The methodology and materials used for the experiments are fully 
discussed in Chapter 4, with the experimental results given in Chapter 5. Chapter 6 discusses 
the results of the experiments. Conclusions are given in Chapter 7, while the 
recommendations for any further work or alternative uses of the data are given in Chapter 8. 
The Appendices will contain the full data sets and their models with all associated details.  
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Chapter 2: Literature Review 
Research of the current literature was undertaken to survey the existing knowledge of Protein 
A and IgG interactions. Focus was given to elution conditions and techniques used, with 
special attention paid to salt type, additives and pH. The current product lines of Protein A 
affinity media were also examined to determine the favoured characteristics of the media and 
how this research will apply to them. The range of IgG therapeutics was also investigated to 
determine the direction of the market and future relevance of this research.  
 
2.1 Protein A and Immunoglobulin G Interactions 
The interactions between Protein A and IgG have only really been studied in detail between 
fragments with either other fragments or an entire molecule. While this has produced some 
incredibly detailed data and insights about certain interactions, it still leaves the overall 
mechanism of interaction between the two molecules largely unknown. The knowledge 
regarding these individual interactions is difficult to apply to whole molecule interactions, as 
the studies do not take account of steric factors or whether the individual parts act alone or in 
combination. There has also been significant work on the interaction within an affinity 
column or in free solution but none have examined the effects as they occur, instead taking 
only snapshots of certain points to determine certain properties. These studies give us some 
knowledge of the interactions but leave a significant gap in the knowledge that this study 
attempts to fill in terms of multiple interaction conditions.  
 
The interaction between the B domain of Protein A and the Fc region of IgG has been studied 
in some depth. As mentioned in Chapter 1, Protein A exhibits an extended shape with a 
number of α-helices. The B domain is made up of two (30) or three (31) of these helices with 
the rest of the molecule folded irregularly. The B domain interacts with both the CH2 and 
CH3 regions of the Fc fragment (shown in Figure 2.1). The bond is formed primarily through 
hydrophobic interactions between the two fragments. While this study (30) also found a 
second bond this was put down to interaction caused by the crystallographic method. This 
was an early study into the interactions between protein A and IgG that first elucidated the 
binding mechanism behind the interaction between the two molecules.  
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Figure 2.1: IgG with significant regions labelled. 
Another, more recent study (32), examined the same interaction between Domain B and the 
Fc region of IgG (the whole molecule was used for this), this time using a quartz crystal 
microbalance (QCM). While this could not determine the exact nature of the binding it could 
determine the adsorption (ka) and desorption (kd) rate constants as well as the maximum 
amount adsorbed. A simple 1:1 binding ratio was found, but at higher surface densities, a 
single IgG could be bound by multiple B fragments. The rate constants determined will be 
compared later with the results of this thesis but while some similarities are possible, it is 
likely that these constants will be different to those obtained due to being only a single part of 
a greater moleule.  
 
 
2.2 Elution conditions for Immunoglobulin G from a Protein A Affinity Column 
A great deal of research has been done into increasing the pH required for effective elution of 
IgG from Protein A. Initial studies in the area established the pH gradient convention that is 
now the basis of all elutions of IgG from Protein A. From there, a variety of methods for 
increasing the pH have been investigated, such as altering the Protein A, matrix effects, 
varying the elution buffer and heat elution. These methods have had mixed success but even 
the more effective methods have had limited uptake, generally because of the cost of using 
relatively unproven methods. Ultimately, the industry remains focused on simple pH-based 
approaches to elution, using proven buffers at standard conditions. 
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One of the early studies (33) into elution proved the efficacy of a simple pH gradient for 
elution. Using a Superose column with immobilised Protein A, a pH gradient from 8 to 3 was 
used to elute IgG. This research also showed that using a pH gradient could be used to at least 
partially separate the different IgG isotypes. The eluted IgG was also extremely pure, a 
feature of current Protein A affinity chromatography. This study established the basis for IgG 
purification that has remained largely unchanged for 30 years. The most improvement that 
has occurred in that time has been in the Protein A media, with higher flows and binding 
capacities achievable, which is discussed in Section (2.3). 
 
Once the basic procedure was well established, research began into improving the process 
with engineering of Protein A to the fore. An early study by Bottomley et al (34) in this area 
focused on altering the B domain of Protein A.  The B domain was altered in one case by C-
terminal truncation and in other cases by site-directed mutagenesis. The truncation proved the 
most effective, showing IgG2 elution at pH 5.0 and IgG1 elution at pH 4.1. By adding some 
site-directed mutagenesis to the truncation full elution was achievable at pH 5.0. The two site 
directed mutants failed as one eluted too easily and was lost under wash conditions, while the 
other showed almost no change, eluting at pH 3.2. The most significant problem with such 
alterations is that the decrease in affinity they cause reduces dynamic binding capacity. This 
trade-off means protein alteration is useful but on a large scale loses much of its appeal due to 
the increase in production time and/or chromatography media that it causes. 
 
Another study (35) focused on a B domain alteration, using a synthetic analogue known as 
the Z domain, shown previously in Figure 1.3. The alterations were made by site directed 
mutagenesis to form two mutants, both with decreased helix size, to evaluate the importance 
of the helices effects on binding. The mutants also had decreased chemical and thermal 
stability compared to the original Z domain.  Both mutants showed improved elution 
properties with 97% and 93% of the IgG eluted at pH 4.5 compared with just 70% for the 
parent molecule. While this kind of protein engineering shows good results, the side-effects 
again decrease its desirability with chemical and thermal stability important for long term 
use, the ability to effectively clean any media and ensuring leaching of the column is 
minimal.   
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To address some of the issues associated with native protein/mutants Teng et al (36) 
synthesised a variety of ligands that mimicked some of the properties of Protein A, while at 
the same time having greater chemical stability. Of the mimetics tested one stood out, with 
IgG capture of 99% and a yield of 98% when bound on a column. It also was able to bind 
human IgG3, unlike Protein A, and a similar variety of mammalian IgGs as Protein A. 
Unfortunately, the mimetic’s strong affinity for IgG means that the elution conditions 
required were even harsher than for Protein A with a pH below 2.9 required. However, the 
chemical stability was extremely good, with no significant loss of performance after 7 days 
(>140 hours) in 1 M sodium hydroxide. This suggests stability for more than 500 wash cycles 
under normal process conditions. Given the large cost of Protein A media such stability can 
be of great value for large scale manufacturers.  
 
Heat elution is another possibility; however it has so far not been used with a Protein A 
derivative. Heat elution is possible with Streptococcal M proteins, which are unstable at low 
temperatures and completely unfold above 40 ºC (37). The unfolding is reversed simply by 
reducing the temperature to below 40 ºC. This study used Protein H from streptococcus 
pyogenes, which can bind a single IgG. Protein H unfolds and loses its affinity for IgG 
between 30 and 35ºC, thus making elution simple, with no change of buffer required. These 
temperatures are not extreme enough to damage the IgG and mutagenesis could be used to 
isolate the IgG binding domain. The structure of such proteins could also be used to develop 
a Protein A derivative with similar properties, or the two proteins could be grafted together. 
This process does still present challenges on a process scale, with uniformly heating a large 
scale column potentially challenging and also the high cost of the media. However, this area 
seems to warrant further investigation. 
 
The last elution method of significance has been identified in a number of studies (38-40) and 
examines the use of arginine in the elution buffer. Arakawa et al (38) were the first to identify 
arginine as a useful eluent due to its use in protein refolding to prevent aggregation. It was 
found that 0.5 M arginine increased the recovery of IgG4 from 46 to 92% at pH 3.8 
(compared to 0.1 M citrate buffer). At pH 4.1 citrate recovery dropped to 18% while arginine 
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remained high at 82%. Recovery was also observed to increase with the concentration of 
arginine; using 0.5 M arginine at pH 4.3 only recovered 48% but with 2.0 M arginine at pH 
4.4 recovery was 84%. IgG1 also responded well going from 6% to 38% and onto 77% 
recovery with 0.1 M citrate, 0.5 M arginine and 2 M arginine respectively. These findings 
were expanded upon by the same group (39) to determine the active part of arginine and if 
other molecules held the same properties. Of the molecules tested actyl-arginine and 
agmatine, both arginine derivatives, were found to be comparable to arginine for elution 
purposes. Of the amino acids tested only histidine showed any effect and was still less 
effective than arginine. Guanidine hydrochloride was also effective but increased antibody 
aggregation. The last study (40) studied the exact interaction between the arginine, IgG and 
Protein A using computer models. It determined that arginine’s positively and negatively 
charged N and C terminals, plus the guandinium group, fuel interactions with polar, charged 
and aromatic groups. This allows arginine to crowd out the Protein A interaction with IgG 
aiding elution and also preventing aggregation by the same effect.           
 
2.3 Protein A Affinity Media Varieties 
As mentioned in the introduction, a number of manufacturers produce a large variety of 
Protein A media. The media vary in a number of ways; bead size, bead structure, surface 
binding mechanism and alteration of the Protein A. This can all be altered to produce better 
results for a given set of conditions. This is most evident in the differentiation between 
process scale and laboratory scale media, with one engineered to produce reasonable 
separation at high flows and pressures while the other is designed to produce excellent 
product resolution but with lower flow and pressure limits. This difference is achieved by 
finer media, which decreases the flow because of the smaller spaces between the media, 
while increasing the binding capacity due to the greater surface area. Dynamic binding 
capacity is also usually reduced for higher flow systems due to the beads requiring greater 
strength through increased cross-linking, which tends to limit their surface area and hence 
ligand density. It should be noted that this is by no means a complete list of all available 
Protein A media. The four manufacturers listed are larger companies that produce multiple 
kinds of media usable at process scale. Of the smaller manufacturers investigated many 
produced media that was largely comparable to one of those listed here. 
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Bio-rad Laboratories (Hercules, CA, USA) produces three different protein A affinity media: 
UNOsphere SUPrA, Affi-Gel Protein A and Affi-Prep Protein A (1). The basic properties of 
these media are shown in Table 2.1. It is clear from the product data that the UNOsphere and 
Affi-Prep media are better for a process scale, with higher flow rates attainable due to their 
more robust matrix materials. UNOsphere also shows the benefits of recombinant Protein A, 
with more than twice the binding capacity of the other two media and the ability to purify a 
range of mAbs (not just IgG). UNOsphere and Affi-gel are roughly similar in price 
(~NZ$2000 for 25 ml) while the Affi-Prep costs almost twice that (NZ$3553 for 25 ml). Affi-
Prep is likely the most expensive because it can support the highest flows (up to 2000 cm/hr). 
Flow rate, along with binding capacity, are amongst the most important characteristics on a 
process scale due to relatively slow flow rates that can be achieved in chromatography 
compared to other process steps such as filtration or centrifugation and the bottle neck that 
this creates in processes.  
Table 2.1: The properties of Bio-rad’s Protein A affinity media (1).   
* Based on human IgG at 10% breakthrough. 
 
Millipore also has three different Protein A media but they are less varied than those 
produced by Bio-rad. The products and their key characteristics are shown in Table 2.2. 
Similar to the UNOsphere media the ProSep media operates at a maximum flow rate of 
approximately 600 cm/h but the binding capacities given greatly exceed those of their Bio-
rad rivals. Porous glass also has some advantages as a matrix material as it is uncompressible 
and is unaffected by almost any condition extremes, e.g. pH, salt, organic solvents etc. The 
pore size of the media is also carefully controlled to allow greater contact time for particles 
below a certain size, thus allowing for greater optimisation depending on the desired product. 
While pore size in polymers can also be controlled it is generally less exact due to their more 
Name Matrix Functional 
Group 
Specificity Capacity 
(Dynamic)* 
Pressure 
Limit/ 
Flow rate  
Working 
pH 
UNOsphere 
SUPrA 
Highly cross-
linked 
polyacrylamide 
polymer 
Recombinant 
protein A 
Antibodies/ 
Immunoglobulins 
25 to 30 
mg/ml 
100-
600cm/h 
3-11 
Affi-Gel 
Protein A 
Cross-linked 
agarose 
Protein A 
2mg/ml 
IgG 6 to 15 
mg/ml 
1 bar 2-10 
Affi-Prep 
Protein A 
Pressure stable 
polymer 
Protein A 
2mg/ml 
IgG 7 to 12 
mg/ml 
70 bar 2-10 
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varied nature. The disadvantage of porous glass is that the uncontrolled, on-spherical particle 
shapes pack into a non-uniform bed, generally increasing dispersion. 
Table 2.2: The properties of Millipore’s Protein A affinity media (2, 3). 
 * Based on human IgG at 10% breakthrough. 
By far the largest range of products belongs to GE Life Sciences with 9 different types of 
Protein A media, as shown in Table 2.3. GE’s matrix of choice is agarose with an average 
bead diameter between 75 and 90µm. Three different forms of protein A are used: native, 
recombinant and a derivative. The Protein A derivative allows for the highest binding 
capacity of any manufacturer’s media (MabSelect SuRe LX) without reducing maximum the 
maximum flow rate. GE’s media has good binding capacity but relatively low pressure limits 
and thus more limited maximum flow rates.    
Table 2.3: The properties of GE’s Protein A affinity media (4). 
Name Matrix Functional 
Group 
Specificity Capacity 
(Dynamic)* 
Pressure 
Limit/ 
Flow rate  
Working 
pH 
MabSelect  85µm highly 
cross-linked 
agarose 
Recombinant 
Protein A (E. 
Coli) 
mAbs >30 mg/ml <200 kPa 
<500 cm/h 
3-10 
MabSelect 
SuRe 
85µm highly 
cross-linked 
agarose 
Alkali-
stabilized 
Protein A-
derived 
(E.coli) 
mAbs >30 mg/ml <200 kPa 
<500 cm/h 
3-12 
MabSelect 
SuRe LX 
85µm highly 
cross-linked 
agarose 
Alkali-
stabilized 
Protein A-
derived 
(E.coli) 
mAbs 60 mg/ml <200 kPa 
<500 cm/h 
3-12 
MabSelect 
Xtra 
75µm highly 
cross-linked 
agarose 
Recombinant 
Protein A (E. 
Coli) 
mAbs >30 mg/ml <200 kPa 
<300 cm/h 
3-10 
nProtein A 
Sepharose 4 
Fast Flow 
90µm 4% 
cross-linked 
agarose 
Native Protein 
A (S. aureus) 
mAbs >30 mg/ml <100 kPa 
<250 cm/h 
3-9 
Protein A Paramagnetic, Native Protein mAbs 27 mg/ml Not Not 
Name Matrix Functional 
Group 
Specificity Capacity 
(Dynamic)* 
Pressure 
Limit/ 
Flow rate  
Working 
pH 
ProSep 
Ultra Plus 
60µm porous 
glass 
Recombinant 
protein A 
mAbs 45 to 55 
mg/ml 
10 bar 1-8.5 
ProSep-vA 
Ultra 
Porous glass 
700Å pores 
Native protein 
A 
mAbs 40 to 55 
mg/ml 
10 bar 1-8.5 
ProSep-vA 
High 
Capacity 
Porous glass 
1000Å pores 
Native protein 
A 
mAbs 20 to 30 
mg/ml 
10 bar 1-8.5 
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Mag 
Sepharose 
Xtra 
spherical, 
highly cross-
linked agarose 
particles 
A (S. aureus) specified specified 
Protein A 
Sepharose 
CL-4B 
90µm 4% 
cross-linked 
agarose 
Native Protein 
A (S. aureus) 
mAbs 20 mg/ml <150 cm/h 3-9 
rmp Protein 
A Sepharose 
Fast Flow 
90µm 4% 
cross-linked 
agarose 
Recombinant 
Protein A (E. 
Coli) 
mAbs >35 mg/ml <100 kPa 
<250 cm/h 
3-10 
rProtein A 
Sepharose 
Fast Flow 
90µm 4% 
cross-linked 
agarose 
Recombinant 
Protein A (E. 
Coli) 
mAbs 50 mg/ml <100 kPa 
<250 cm/h 
3-10 
* Based on human IgG at 10% breakthrough. 
Invitrogen produces six different Protein A affinity media but only two can be bought in 
amounts large enough for process scale, which are shown in Table 2.4. These media are 
largely similar in pressure limit and dynamic capacity to those produced by Millipore. 
However, Invitrogen uses a complex polymer to achieve strengths similar to those of the 
glass beads used by Millipore, with the same maximum flow as Bio-rad’s Affi-Prep media 
that also uses a polymer matrix.  
 
Table 2.4: The properties of Invitrogen’s Protein A affinity media (5). 
Name Matrix Functional 
Group 
Specificity Capacity 
(Dynamic)* 
Pressure 
Limit/ 
Flow rate  
Working 
pH 
POROS 
MabCapture 
A 
Cross-linked 
poly(styrene-
divinylbenzene) 
Recombinant 
Protein A 
mAbs 40 to 50 
mg/ml 
10 bar 
2000 cm/h 
2-10 
POROS A 
50µm 
Cross-linked 
poly(styrene-
divinylbenzene) 
Recombinant 
Protein A 
mAbs 30 to 38 
mg/ml 
10 bar 
2000 cm/h 
2-10 
* Based on human IgG at 10% breakthrough. 
 
Pierce Protein Biology Products (part of Thermo Fisher Scientific) produces a wide range of 
Protein A media, as well as mixed Protein A and Protein G media. Table 2.5 shows the four 
kinds of Protein A media Pierce produces, all of which are also produced as mixed Protein A 
and G with the same properties other than binding capacity. The dynamic binding capacities 
(using human IgG) for the Protein A/G mix are 25mg/ml, 7mg/ml, 20mg/ml, 28mg/ml for the 
Plus Agarose, Agarose, Ultralink and UltraLink Plus, respectively. The agarose media is 
largely similar to those produced by GE while the Ultralink media is most like Bio-rad’s 
UNOsphere media. 
20 
 
Table 2.5: Pierce Protein A media properties (6). 
Name Matrix Functional 
Group 
Specificity Capacity 
(Dynamic)* 
Pressure 
Limit/ 
Flow rate  
Working 
pH 
Protein A 
Plus Agarose 
6% Cross-
linked Agarose 
Native Protein 
A 
mAbs >34 mg/ml <1.5 bar 
30 cm/h 
2-14 
Recombinant 
Protein A 
Agarose 
6% Cross-
linked Agarose 
Recombinant 
Protein A 
mAbs 15 to 17 
mg/ml 
<1.5 bar 
30 cm/h 
2-14 
Protein A 
Agarose 
6% Cross-
linked Agarose 
Native Protein 
A 
mAbs 12 to 19 
mg/ml 
<1.5 bar 
30 cm/h 
2-14 
Protein A 
UltraLink 
Resin 
Highly Cross-
linked 
Polyacrylamide 
Native Protein 
A 
mAbs 16 mg/ml 6.9 bar 
3000 cm/h 
1-13 
Protein A 
Plus 
UltraLink 
Resin 
Highly Cross-
linked 
Polyacrylamide 
Native Protein 
A 
mAbs 30 mg/ml 6.9 bar 
3000 cm/h 
1-13 
* Based on human IgG at 10% breakthrough. 
By comparing the various media from all the manufacturers a number of conclusions can be 
drawn. On a process scale average bead diameter must be approximately between 40 and 
100µm. While agarose (the most established material) remains popular, a number of 
alternative media materials are now in use and perform as well as or better than agarose in 
many cases. Native Protein A remains in use for a number of media, but it is clear that in 
order to reach the highest binding capacities recombinant Protein A or a derivative is 
required. The different media show a range of dynamic binding capacities from 6 to 60 
mg/ml, but the majority fall between 20 and 50 mg/ml. While the flow rates vary greatly 
between media the extremely high flows need to be treated with a level of suspicion, because 
while it may be possible to have a flow rate above 500 cm/h there is always a trade off 
between flow rate and binding capacity due to the influence of residence time.  Thus, while 
2000 cm/h might be achievable on a 20 cm column the residence time would only be 36 
seconds and barely any binding would have time to occur. The dynamic binding capacities 
quoted were for between 3 and 6 minutes, which limits the flow rate in standard columns of 
between 15 and 25 cm to 300 to 500 cm/h respectively.      
 
In 2003 Hahn et al (7) produced a comparative study of 15 different Protein A media, shown 
in Table 2.6. Of these products most still exist either in the same or an improved form and 
have appeared in the previous product tables. This study used polyclonal IgG and between 
0.5 and 2 ml of media in a 2.5 cm tall column, which are not the desired parameters but 
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should still give some insight into the performance of the media. Mabselect was found to be 
the best (highest binding capacity) at 50 and 100 cm/h (residence time greater than 1.5 
minutes) while Poros 50 A was found to be the best at higher flows. This study also found 
that at 200 cm/h or above (less than 45 s residence time) five types of media showed no 
binding whatsoever. This fits with the data provided by manufacturers and reinforces the fact 
that the ability to achieve high flows is often limited not by the pressure but the binding 
capacity. Furthermore, the authors noted that the desired residence time had a large effect on 
the best media for the job with Poros 50 A performing better when residence time was less 
than 3 minutes but rPrA Sepharose Fast flow the better option for any longer residence time.  
Table 2.6: Hahn et al chosen Protein A media (7). 
Name Manufacturer Matrix  Mean Particle 
Diameter (µm) 
Ligand Density 
(mg/ml) 
rProtein A 
Sepharose Fast 
Flow 
Amersham 
Biosciences (now 
GE Life Sciences) 
Cross-linked 
agarose 
90 4-6 
Protein A 
Sepharose 4 Fast 
Flow 
GE Life Sciences Cross-linked 
agarose 
90 4-6 
MabSelect GE Life Sciences Cross-linked 
agarose 
85 N/A 
IPA-500 RepliGen Corp. Cross-linked 
agarose 
90 N/A 
Protein A Ceramic 
HyperD F 
Biosepra Polyacrylamide gel 
in ceramic macro-
bead 
50 4-5 
Prosep-A High 
Capacity 
Millipore Porous Glass 75 N/A 
Prosep-rA High 
Capacity 
Millipore Porous Glass 75 N/A 
Poros 50 A High 
Capacity 
PerSeptive 
Biosystems (now 
Invitrogen) 
Polystyrene-
divinylbenzene 
50 N/A 
UltraLink 
Immobilised 
Protein A Plus 
Pierce Polymeric 60 N/A 
UltraLink 
Immobilised 
Pierce Polymeric 60 N/A 
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Protein A 
Affi-Gel Protein A Bio-rad Cross-linked 
agarose 
N/A 2 
Affi-Prep Protein 
A 
Bio-rad Polymeric N/A 2 
Protein A Agarose 
4XL 
Affinity 
Chromatography 
Ltd 
Cross-linked 
agarose 
N/A N/A 
Protein A Cellthru 
300 
Sterogen 
Bioseparations 
N/A 200-300 N/A 
AF-Protein A 
Toyopearl 650 M 
Tosoh Biosep Polymethacrylate 80 N/A 
 
Hahn et al did another study in 2006 (41) into the long term effects of industrial scale 
purification on protein A media. Only three media were used for this study; MabSelect SuRe, 
MabSelect Xtra and Prosep-vA Ultra. The media was tested after 50 consecutive purification 
cycles (equilibration, binding, elution and cleaning) to determine any loss of performance or 
additional leakage from the column. None of the media showed a loss of purification 
performance over the test period. MabSelect SuRe showed the least leakage with less than 4 
ppm in any run. Xtra had leakage between 5-35 ppm with no noticeable increase with number 
of runs while Prosep was generally less than 40 ppm, but in later cycles did show some larger 
outlying results. Overall this study showed that Protein A media is relatively stable over 
multiple cycles and this stability is improving with the matrix and ligand advances.   
 
2.4 Immunoglobulin G Therapeutics 
There are at least 23 different mAb therapeutics in use, that treat a variety of different 
diseases, shown in Table 2.7. Of the therapeutics shown, 17 utilise IgG which illustrates the 
importance of IgG, and its purification process, in the pharmaceutical industry. These 
therapeutics are potentially just the tip of the iceberg with many more in development (27) 
and a bright future with the rise of transgenic animals and crops to potentially provide 
cheaper upstream costs. IgG’s ability to specifically target undesirables allows for targeted 
treatment of a huge range of diseases and lower doses to decrease negative side effects and 
speed recovery. 
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Table 2.7: Approved and commercialised mAb therapeutics (8).  
Generic 
Name 
Molecule type Disease(s) Treated Company Approval 
Status 
Golimumab Human Anti-TNFα Rheumatoid arthritis, active 
psoriatic arthritis and active 
ankylosing spondylitis 
Centocor 2009 FDA 
2009 EMEA 
Certolizumab Pegylated humanized 
Fab fragment IgG1 TNF-
α 
Crohn’s disease UCB Pharma 2008 FDA 
Eculizumab Humanized IgG2/4κ that 
binds to C5 
Chronic orphan blood 
disorder and  paroxysmal 
nocturnal hemoglobinuria  
Alexion 
Pharmaceuticals 
2007 FDA 
2007 EMEA 
Ranibizumab Recombinant humanized 
IgG1κ mAb Fab 
Neovascular age-related 
macular degeneration 
Genentech/ 
Novartis 
2006 FDA 
2007 EMEA 
Panitumumab Human, IgG2κ, anti-
EGF receptor 
Metastatic colorectal cancer Amgen/ 
Abgenix 
2006 FDA 
2007 EMEA 
Natalizumab Recombinant Humanized 
IgG4κ 
Crohn’s disease, Multiple 
Sclerosis 
Biogen IDEC 2004 FDA 
2006 EMEA 
Nimotuzumab Humanized IgG1 anti-
EGF receptor 
Epithelial cancer YM Biosciences/ 
Biocon 
2005 China 
2006 India 
Bevacizumab Humanized IgG1 anti-
VEGF 
Metastatic colorectal cancer Genentech/ 
Roche 
2004 FDA 
2005 EMEA 
Omalizumab Humanized (anti-IgE Fc) Allergy Genentech/ 
Novartis 
2003 FDA 
2005EMEA 
Cetuximab Chimeric IgG1κ anti-
EGF receptor 
Epidermal growth factor 
receptor expressing 
metastatic colorectal cancer  
ImClone/ 
Bristol-Myers 
Squibb 
2004 FDA 
2004 EMEA 
Efalizumab Humanized Ig anti-
CD11a 
Psoraisis Genentech/ 
Roche 
2003 FDA 
2004 EMEA 
I-131 
tositumomab 
Murine, IgG2aλ anti-
CD20, radiolabeled  
(I-131) 
Non-Hodgkin’s lymphoma  Corixa/ 
GlaxoSmithKline 
2003 FDA 
Ibritumomab 
tiuxetan 
Murine, IgG1κ, anti-
CD20, radiolabeled (Y-
90) 
Non-Hodgkin’s lymphoma IDEC 
Pharmaceuticals 
2002 FDA 
2004 EMEA 
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Adalimumab Human anti-TNFα Crohn’s disease, rheumatoid 
arthritis, ankylosing 
spondylitis 
Abbott 
Laborartories 
2002 FDA 
2003 EMEA 
I-131 ch-TNT Chimeric IgG1κ, anti-
DNA associated 
antigens, radiolabeled (I-
131) 
Advanced lung cancer Shanghai 
Medipharm 
Biotech 
2003 China 
Alemtuzumab Humanized, IgG1κ, anti 
CD52 
Chronic lymphocytic 
leukaemia 
Millenium/ 
ILEX Partners 
2001 FDA 
2001 EMEA 
Gemtuzumab 
ozogamicin 
Humanized, IgG4κ, anti-
CD33, immunotoxin 
Relapsed acute myeloid 
leukaemia 
Celltech/Wyeth 2000 FDA 
Infliximab Chimeric anti-TNFα Rheumatoid arthritis, 
Crohn’s disease 
Centocor 1998 FDA 
1999 EMEA 
Trastuzumab Humanized, IgG1κ, anti-
ER2 
HER2 over-expressing 
metastatic breast cancer 
Genentech 1998 FDA 
2000 EMEA 
Palivizumab Humanized anti-F-
protein 
Respiratory Syncitial viral 
disease 
MedImmune 1998 FDA 
1999 EMEA 
Basiliximab Chimeric anti-IL-2 
receptor 
Kidney transplant rejection Novartis 1998 FDA 
1998 EMEA 
Rituximab Chimeric, IgG1κ, anti-
CD20 
Relapsed non-Hodgkin’s 
lymphoma 
IDEC/ 
Genentech 
1997 FDA 
1998 EMEA 
Daclizumab Humanized anti-IL-2 
receptor 
Refactory unstable angina, 
Allograft rejection 
Hoffmann-
LaRoche 
1997 FDA 
1999 EMEA 
Abciximab Chimeric Fab fragment, 
IgG1 IIb/IIIa 
glycoprotein 
Inhibits platelet aggregation 
following angioplasty 
Centocor/ Eli 
Lilly & Co. 
1994 FDA 
Muromomab Murine, IgG2a anti-CD3 Acute rejection of organ 
transplantation 
Ortho Biotech 1986 FDA 
1987 EMEA 
 
 
2.5 Industrial Production of Monoclonal Antibodies 
The industrial process for the production of monoclonal antibodies generally adheres to a set 
structure with some minor variation in production and purification techniques. The main form 
of production is by mammalian cell culture although transgenic livestock and plants have 
increasing potential due to the cost savings they provide. A variety of purification techniques 
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are used in the process with the most costly being the various chromatography steps used 
because of the high cost of the media required. 
 
 
The growth of mAbs in pharmaceuticals has seen a large increase in the number and size of 
production facilities as shown in Table 2.8 and Figure 2.2. The table also shows the 
significant cost of such facilities, which in turn affects the cost of the pharmaceutical 
products. The graph shows an increase in facility area over the years while the bioreactor size 
shows more gradual growth. This is likely due to advances in culture methods allowing larger 
production from cultures while facility size must increase to allow for greater purification 
capacity.  
  
Table 2.8: mAb manufacturing facilities size and cost between 2000 and 2009 (9). 
Manufacturing Facility Date Facility 
Completed 
Capital Investment 
(US$M) 
Area (sq ft) Bioreactor 
Capacity (L) 
Genentech – Vacaville, CA, USA 2000 250 310000 96000 
Imclone – Branchburg, NJ, USA 2001 53 80000 30000 
Biogen – NC, USA 2001 175 245000 90000 
Boehringer ingelheim expansion – 
Biberach Germany 
2003 315 - 90000 
Lonza biologics expansion – 
Portsmouth, NH, USA 
2004 207 270000 60000 
Amgen – West Greenwich, RI, 
USA 
2005 500 500000 180000 
Genentech – Oceanside, CA, USA 2005 380 470000 90000 
Imclone – Branchburg, NJ, USA 2005 260 250000 99000 
Biogen – Hillerod, Denmark 2007* 350 366000 90000 
Lonza biologics – Tuas, Singapore 2009* 250 - 80000 
Genentech expansion – Vacaville, 
CA, USA 
2009* 600 380000 200000 
*Expected Completion date 
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Figure 2.2: mAb facility production size from 2000-2009 (9). 
The basic process for production and purification of pharmaceutical mAbs (10) is shown in 
Figure 2.3. The process is defined in six steps, all of which, excepting cell culture, are 
different purification steps, although two are chromatographic processes and two filtration 
processes. The production costs for a sample case (10ton/yr production facility) have been 
examined based on the process steps as shown in Tables 2.9 and 2.10 (10). The cost of raw 
materials for purification make up a significant part of the cost of goods for the drug product 
as well as contributing to the facility costs (purification needs infrastructure and floor space), 
which can be seen in Table 2.9. Breaking down the purification material costs by step (Table 
2.10) it can be seen that Protein A chromatography media makes up half of these costs. This 
highlights the importance of understanding the IgG-Protein A interaction in economic terms 
given the high costs of these drugs vital to the survival of many. 
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Figure 2.3: Basic process for purification of pharmaceutical mAbs (10).  
 
Table 2.9: Cost of mAb production (10). 
Total Cost of Goods Estimate (drug product) US$/g 
Upstream (medium cost of $8/L) 2 
Purification raw material costs 4 
Facility depreciation 5 
Staff salaries 5 
Fill-finish cost per vial 10 
Total COGs (1g/vial) 26 
 
Table 2.10: Breakdown of mAb purification costs based on unit operation and materials (10). 
Purification costs per unit operation US$/g  Top Five Raw Material Costs US$M/yr 
Harvest (centrifugation and clarification)  1.02 Protein A resin 13.1 
Affinity Chromatography (Protein A) 2.03 0.2µm prefilters 5.6 
Anion-exchange Chromatography 0.35 VRF Membrane 4.4 
Virus Removal Filter 0.50 Buffer for harvest and ProA 3.6 
Ultra/Dia-filtration 0.12 ProA step wash salt 3.5 
Total cost of purification 4.02 Total Purification Process Cost 40.2 
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Chapter 3: Modelling Equations and Programs 
Molecular interactions are heavily studied and there are a large number of ways to produce 
models for such interactions. There are a variety of equations used to model interactions, 
depending upon the kind of interaction and the environment that it is occurring in. Once the 
type of interaction is established, a number of different programs can be used to model the 
interaction. These vary from ground up models where all the equations, parameters and data 
points must be entered by the user to more specialised software that have the models mostly 
built and require only certain aspects to be defined. 
  
3.1 Reaction Equations 
There are a variety of equations used to describe the reactions and interactions between 
molecules (42). One of the first considerations is the phase of the reactants; as reactants in 
different phases limit the reaction to the interface between the phases. However, as all the 
experiments in this thesis are carried out with both reactants in aqueous solution, even the 
immobilised Protein A (see description of SPR, Chapter 2) this area will be ignored. Other 
considerations are temperature, concentration of reactants, pressure, and presence of catalysts 
and/or inhibitors. Pressure in a liquid system does not have a large effect on the interaction, 
as it does not cause a significant alteration in the dynamics of the molecules within the 
system unlike a gaseous system. Thus, pressure does not need to be accounted for, in the 
absence of orders of magnitude changes. The remaining factors can all have significant 
effects and must be controlled or accounted for during experimentation. 
 
Temperature has a large effect on reactions, particularly when using biological molecules as a 
significant temperature shift can completely stop a reaction due to the breakdown of the 
molecules. Biological reactions are often limited to between 1ºC and 40ºC as they are 
aqueous and prone to heat degradation beyond body temperatures. Between these 
temperatures, reactions are subject to the Arrhenius equation (Equation 1), which is defined 
empirically for each different reaction. Given that the equation is empirically defined, to use 
the equation the values need to be obtained from the literature or by experimental work. 
Alternatively, if the reactions are all performed at the same temperature then no correction of 
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the rate constant is required and the values are unnecessary. Fortunately, the XPR36 and 
other SPR devices are temperature-controlled for consistency of results, allowing the 
Arrhenius relationship (Eqtn[1]) to be ignored.  
݇ = ܣ݁ିாೌ/(௞ಳ்)          [1] 
where: k = the rate constant for the reaction 
 A = the pre-exponential factor 
 Ea = the activation energy of the reaction 
 kB = the Boltzmann constant 
 T = temperature in Kelvin 
 
The remaining factors determine the equation that is used for the reaction. If there is no 
catalyst or inhibitor then the Langmuir equation can be used to describe the system. The 
Langmuir equation assumes a limited number of binding sites on a set number of molecules, 
usually adsorbed onto a surface. This equation is useful for SPR binding and similar systems 
such as HPLC and ELISA. The initial equation (Equation 2) gives the equilibrium constant, 
which occurs when the reaction rate is zero. From this the equation can be rearranged to give 
a rate equation (Equation 4) at equilibrium. The rate equation can then be used to model an 
interaction or be modelled from an interaction. This can also be done by combining two 
standard rate equations for the association and dissociation (not shown here). 
ܭ = [஺஻][஺][஻]           [2] 
ܭ = ௞ೌ
௞೏
= [஺஻][஺][஻]           [3] 
ݎ = 0 = ݇௔[ܣ][ܤ]− ݇ௗ[ܣܤ]         [4] 
where: K = the equilibrium constant 
 [X] = concentration of species X 
 ka = the association constant 
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 kd = the dissociation constant 
 r  = reaction rate   
The presence of a catalyst can be dealt with in a number of ways for the purposes of reaction 
modelling. Either the standard rate equation can be applied, and the difference between the 
rate constants can be compared with and without catalyst, or a more specialised equation can 
be applied. In biochemistry enzymes are the most frequent catalysts and are described by the 
Michaelis-Menten equation as shown in Equation 5. This equation assumes a single 
reactant/substrate binding one catalyst to convert to a product. Inhibition is dealt with in a 
similar fashion with Km becoming Kmapp in the Michaelis-Menten equation which is described 
in Equation 6. Where Michaelis-Menten does not apply empirical results coupled with the 
standard rate equation can be used to study the effect of the inhibition. 
ݎ = ோ೘ೌೣ[ௌ]
௄೘ା[ௌ]             [5] 
ܭ௠
௔௣௣ = ܭ௠(1 + [ூ]௄೔)            [6] 
Where: Rmax = the maximum rate achievable when the catalyst is saturated with substrate 
 [S] = substrate (reactant) concentration 
 Km = the Michaelis constant is the substrate concentration at half Rmax 
 Kmapp = the Michaelis constant when inhibition occurs 
[I] = inhibitor concentration 
Ki = the inhibitor’s dissociation constant 
 
3.2 Langmuir Equations 
Langmuir equations are suitable for the interaction between IgG and Protein A because they 
are the only molecules that act in the binding mechanism and the immobilised protein A acts 
similarly to a molecule in free solution. The first equation to be tested was a simple single 
interaction between the IgG and Protein A with a 1:1 binding ratio. The interaction and rate 
equations for this are shown below in Equations 1 and 2 respectively. This is the simplest 
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form a kinetic equation can take and is common for chemical reactions and reactions 
involving smaller biological molecules. 
ܫ݃ܩ +  ܲݎ݋ܣ ↔ ܫ݃ܩܲݎ݋ܣ          [1] 
ݎூ௚ீ௉௥௢஺ = ݇௔ ∗ [ܫ݃ܩ] ∗ [ܲݎ݋ܣ]− ݇ௗ ∗ [ܫ݃ܩܲݎ݋ܣ]      [2] 
where:  rIgGProA = the change in concentration of IgGProA complex over time 
 ka = the association constant between IgG and protein A 
 kd = the dissociation constant between IgG and protein A 
 [x] = the concentration of a given species  
 
Greater complexity is simple to add to the standard equations if different ratios or additional 
binding sites are present. Equations 3 to 6 show the equations for a 3:1 binding ratio between 
IgG and Protein A. These equations can easily be expanded to any number ratio of x:1 with 
Equations 4 and 6 remaining the same at either end and additional equations in the middle 
taking the same form as Equation 4. For IgG and Protein A a 2:1 ratio is likely, as noted in 
the literature (18, 19) with anything higher than this unlikely due to the steric inhibition 
caused by the large size of IgG compared with Protein A. There is also some possibility of 
multiple Protein A’s binding to a single IgG (32) but as long as the surface density of Protein 
A is limited, this should not have a significant effect.  
ܫ݃ܩ + ܲݎ݋ܣ ↔ ܫ݃ܩܲݎ݋ܣ + ܫ݃ܩ ↔ ܫ݃ܩ2ܲݎ݋ܣ+ ܫ݃ܩ ↔ ܫ݃ܩ3ܲݎ݋ܣ….  [3] 
ݎூ௚ீ௉௥௢஺ = ݇௔ଵ ∗ [ܫ݃ܩ] ∗ [ܲݎ݋ܣ]− ݇ௗଵ ∗ [ܫ݃ܩܲݎ݋ܣ]− ݇௔ଶ ∗ [ܫ݃ܩ] ∗ [ܫ݃ܩܲݎ݋ܣ] + ݇ௗଶ ∗[ܫ݃ܩ2ܲݎ݋ܣ]           [4] 
ݎூ௚ீଶ௉௥௢஺ = ݇௔ଶ ∗ [ܫ݃ܩ] ∗ [ܫ݃ܩܲݎ݋ܣ]− ݇ௗଶ ∗ [ܫ݃ܩ2ܲݎ݋ܣ]− ݇௔ଷ ∗ [ܫ݃ܩ] ∗ [ܫ݃ܩ2ܲݎ݋ܣ] +
݇ௗଷ ∗ [ܫ݃ܩ3ܲݎ݋ܣ]          [5] 
ݎூ௚ீଷ௉௥௢஺ = ݇௔ଷ ∗ [ܫ݃ܩ] ∗ [ܫ݃ܩ2ܲݎ݋ܣ]− ݇ௗଷ ∗ [ܫ݃ܩ3ܲݎ݋ܣ]    [6] 
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Another source of complexity arises from the multiple binding sites on Protein A allowing for 
a number of different binding mechanisms. The basic equations for this are Equations 7 and 8 
when the binding ratio is 1:1. These can be expanded to a multiple binding model through 
Equations 9 through 11. Multiple binding sites combined with multiple binding represents 
one of the most complicated, but likely, models that could be required for the interaction of 
IgG and Protein A. When such a model is implemented careful checking is required to ensure 
all factors and pathways have been accounted for. A disadvantage of using multiple binding 
sites is that each new site introduced to the model is effectively introducing another fitting 
parameter, which can obscure the simplest mechanistic understanding. Generally, the 
simplest fitted model that can adequately explain the data is the most likely to reflect reality.  
ܫ݃ܩ + ܲݎ݋ܣ ↔ ܫ݃ܩܲݎ݋ܣ௫           [7] 
ݎூ௚ீ௉௥௢஺ೣ =  ݇௔௫ ∗ [ܫ݃ܩ] ∗ [ܲݎ݋ܣ]− ݇ௗ௫ ∗ [ܫ݃ܩܲݎ݋ܣ௫]      [8]  
ܫ݃ܩ + ܫ݃ܩܲݎ݋ܣ௫ ↔ ܫ݃ܩ2ܲݎ݋ܣ௫௬        [9] 
ܫ݃ܩ + ܫ݃ܩܲݎ݋ܣ௬ ↔ ܫ݃ܩ2ܲݎ݋ܣ௫௬                  [10] 
ݎூ௚ீଶ௉௥௢஺ೣ೤ = ݇௔௫௬ ∗ [ܫ݃ܩ] ∗ [ܫ݃ܩܲݎ݋ܣ௫] + ݇௔௬௫ ∗ [ܫ݃ܩ] ∗ ൣܫ݃ܩܲݎ݋ܣ௬൧ − ݇ௗ௫௬ ∗
ൣܫ݃ܩ2ܲݎ݋ܣ௫௬൧ − ݇ௗ௬௫ ∗ [ܫ݃ܩ2ܲݎ݋ܣ௫௬]                  [11] 
 
There are a number of other considerations that could potentially affect the model but not the 
interaction equations. A mass transport limited system would affect the reaction by limiting 
the amount of IgG available to interact as shown in Equations 12 and 13. If there are mass 
transport effects, it will be clear from the data based on interactions at different flow rates. 
Another potential effect is IgG aggregation, which could reduce the amount of IgG available 
for interaction with the Protein A, as shown in Equations 14 and 15. Aggregation is known to 
occur under a variety of conditions (29), but is unlikely to have a large effect on the current 
experiments for most of the conditions used. 
ܫ݃ܩ∗ ↔ ܫ݃ܩ                     [12] 
ݎூ௚ீ = ݇௠,௜௡ ∗ [ܫ݃ܩ∗] − ݇௠,௢௨௧ ∗ [ܫ݃ܩ]                 [13] 
Where: IgG* = IgG in free solution 
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 IgG = IgG within reaction zone 
 km,in/out = the transport constant for movement in/out 
ܫ݃ܩ + ܫ݃ܩ ↔ 2ܫ݃ܩ                    [14] 
ݎଶூ௚ீ = ݇௔,௔௚ ∗ [ܫ݃ܩ]− ݇ௗ,௔௚ ∗ [2ܫ݃ܩ]                 [15] 
 
3.3 Analysis Software 
A number of different software programs were used to ensure accuracy and verify results 
when performing the modelling of the interactions. The XPR36 has its own software 
(ProteOn Manager) for data output and some data analysis. Scrubber (Biologic Software, 
Canberra, Australia) performs many of the same functions as the inbuilt XPR36 software but 
with greater user control and also can provide limited modelling ability. ClampXP (Biologic 
Software, Canberra, Australia) is a modelling program that allows for user defined reaction 
equations and uses the output data from Scrubber. Stella (Isee Systems, Lebanon, NH, USA) 
is a program that can model dynamic systems by finite difference, with the user creating the 
system and defining virtually every aspect therein. Microsoft Excel (Microsoft, Redmond, 
WA, USA) can also be used as a data modelling program and could also be used to refine the 
data but this would be relatively time consuming compared to the more specialised programs.   
 
The ProteOn Manager software (Bio-Rad, Hercules, CA, USA) that comes with the ProteOn 
XPR36 provides raw, processed and analysed data outputs in both graphical and numerical 
form. The raw data can be tidied up in a number of ways using ProteOn software. Blank 
channels and/or samples can be referenced to remove pH, salt and non-specific binding 
effects from the data. Interspot (the empty space between the ligand channels) referencing 
can be used in a similar manner to blank or control channels. Artifact (large aggregates, air 
bubbles etc that appear as large spikes on the output graphs) removal is also possible but only 
automatically by the program (not manually). Alignment of the start and end of the injection 
curves is possible either manually or using the auto-correcting magic wand tool. Baseline 
alignment to zero is also only available through the program tools. All these tools allow the 
elimination of unwanted effects on the data, allowing the interaction between IgG and Protein 
A to be isolated and studied. Once this has occurred, the program can then model the reaction 
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in a variety of ways. The processed data can be modelled with a simple 1:1 binding ratio 
Langmuir model or a 2:1 bivalent model (as shown below in Figure 3.1) with a mass-transfer 
limited model and an equilibrium model as well. The models are done almost exclusively by 
the program, with analyte concentration and injection start and end times being the only user 
controlled parameters. Overall, the ProteOn software is largely controlled by automated 
algorithms buried within the program itself, making it easy to use but difficult to control or 
alter when it is not performing as desired. 
 
 
Figure 3.1: A bivalent model of IgG and Protein A using ProteOn software. The data is a dilution series 
(each step is half the previous) of IgG and a blank. The dashed lines are the model. 
 
Scrubber was developed for Biacore systems but has a ProteOn version. It is largely similar 
in function to the ProteOn Manager software, providing most of the same data refining 
functions, as shown by the output data shown in Figure 3.2 below. The main difference 
between the two programs when it comes to data refining is the amount of user control 
allowed, with Scrubber providing almost complete user control, compared with the far more 
constrained ProteOn software. Injection alignment, referencing, baseline alignment and 
artefact removal are all available, with additional functions allowing cropping and removal of 
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any specific data points or sets. Scrubber also provides basic kinetic modelling but is limited 
to simple 1:1 binding kinetics. It also provides a statistical analysis of the amount bound and 
saturation. Scrubber’s greater user control allows better control of the processed data but does 
make it more time consuming. The modelling package remains inadequate for anything 
beyond the most basic interaction model (1:1 binding), whereas ClampXP provides additional 
versatility. 
 
 
Figure 3.2: Data output screen of Scrubber. 
 
ClampXP (Biologic Software, Canberra, Australia) is an interaction modelling program that 
combines data with user-defined equations to produce virtually any model desired by the 
user. It is designed to integrate with Scrubber by taking the processed data and providing a 
better fit than Scrubber can achieve. The program allows as many compounds and reactions 
as the user desires to define, although it is limited to two reactants and one product within any 
single reaction. The program is based on Langmuir kinetics, with user inputs for association 
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and dissociation constants for each reaction. The user chooses the parameters they wish to be 
fitted for the model, with virtually all values able to be fitted. ClampXP then runs the model 
against the data and optimises the desired parameters until convergence is reached or the user 
stops the simulation, as shown in Figure 3.3 below. Error outputs are given for each 
parameter and the overall fit. Monte Carlo simulation can be used in addition to the standard 
simulation. ClampXP will stop if it detects an irrelevant parameter so that parameter can be 
removed or re-evaluated. All these factors make ClampXP easy to use and very effective for 
modelling interactions from an SPR, which is why it was chosen as the main modelling 
program for this thesis. 
 
 
Figure 3.3: A screenshot of a ClampXP optimised model of the interaction between IgG and Protein A.  
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Stella (Isee Systems, Lebanon, NH, USA) is a standalone program that can be used for 
modelling of interactions, due to its versatility. The program works through visual flow 
diagrams, with variables and equations each defined in their own separate units, as shown in 
Figure 3.4. In the diagram (Figure 3.4) the boxes represent stocks of the individual 
compounds and fill or empty depending on their concentration. The thick arrows represent 
reaction pathways (flows), each with a user-defined equation, while the small arrows 
represent the parameter values used in those equations. As an example, the thick arrow going 
from the box labelled “bivalent binding” to  the ligand site A box is labelled “Bivalent 
Dissociation to A” and contains the equation ݎ = ݇ௗ௕[ܫ݃ܩ2ܲݎ݋ܣ] and hence has small 
arrows from the kdb constant and the bivalent binding box. The full model is shown and 
explained in Appendix A. The visual aspect can make it easier to conceptualise and follow 
the progression of the reactions and their constituents within the system. Unfortunately, it is a 
great deal more difficult to optimise the model when fitting the data, as there is no inbuilt 
function in the program and no direct way to match a data set and the model produced. The 
model data could easily be broken down and examined in parts easily to see the effect of any 
one mechanism or compound and data was easily available from output tables. Ultimately, 
the lack of an optimisation function makes this program unsuited to large scale modelling of 
interactions, despite the useful conceptualisation features of Stella. 
 
Microsoft Excel (Microsoft, Redmond, WA, USA) is a spreadsheet program with a large 
variety of add-ons and even the ability to code new programs when using Visual Basic. While 
Excel is not designed specifically for the purpose of modelling interactions its flexibility 
allows for enough user control to create virtually any model desired. Raw or processed data 
can be used in Excel from Scrubber or ProteOn Manager. All data points can be viewed on 
the spreadsheet or easily plotted on a graph, which allows full user control to examine, alter 
or remove any of the data. Any model can be used if the user knows how to create it. By 
setting up an error/difference column between the data and the model the solver add-in can be 
used to optimise the results by minimising the error. Euler’s method can be applied to the 
Langmuir rate equations to produce a model in Excel (which can be checked for accuracy by 
decreasing the step size). This makes Excel effective for modelling interactions but somewhat 
time-consuming. Excel was used to verify some of the results gained from ClampXP for this 
thesis because of the complexities of dealing with the large data sets and setting up the 
models.                
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Figure 3.4: A visual flow diagram from Stella for the interaction mechanism between IgG and Protein A.
Ligand Site A
Free Ligand
Association A
Dissociation A
Ligand SIte B
Association B
Dissociation B
kaA
kaB
kdB
kdA
Site A to bivalent
Cbulk
Site B to bivalent
Total Bound
Bivalent Binding
Bivalent Dissociation to A
Bivalent Dissociation to B
Cbulk
kdB
kdA
kaB
Cfeed
Injection time
kaA
RU
Steric inhibition
39 
 
Chapter 4: Experimental Materials and Methodology 
Virtually all experimental work was done on the ProteOn XPR36. A great deal of 
optimisation was needed before the experiments produced useful data and ongoing problems 
with the interaction and SPR system. All work was performed in the Biological Sciences 
building, fifth floor laboratory at the University of Canterbury. 
 
4.1 Materials and Equipment 
All the IgG used was polyclonal, from human serum, reagent grade ≥95% pure (product code 
I4506), obtained from Sigma-Aldrich (St. Louis, MO, USA). Two forms of Protein A were 
used. The first, from Sigma-Aldrich, was recombinant Protein A, expressed in E. Coli (from 
Cowan strain, MW 45kDa), reagent grade ≥95% pure (product code P7837). The second, 
from Sino Biological (Beijing, China), was also recombinant Protein A, expressed in E. Coli 
(MW 34kDa), reagent grade ≥95% pure (catalogue code 10600-P07E) but had a his-tag in 
place of the cell wall anchoring section of the protein. A variety of analytical grade chemicals 
were used for the experiments, including sodium chloride, sodium dihydrogen 
orthophosphate, disodium hydrogen orthophosphate, sodium hydroxide, sodium acetate, citric 
acid, acetic acid, hydrochloric acid, glycine, sodium dodecyl sulfate, tween-20, EDTA, 
ethanolamine hydrogen chloride, nickel sulfate, potassium dihydrogen orthophosphate, 
EDAC, NHS and imidazole. These chemicals were made up into a variety of buffers using 
purified (Milli-Q) water. 
 
An Eppendorf (Hamburg, Germany) Centrifuge 5415 R was used for sample centrifugation to 
ensure the amount of aggregate was minimised. The NanoDrop 1000 (Thermo Fisher 
Scientific, Waltham, MA, USA) was used to check the concentration of IgG and Protein A  in 
solutions before use in the SPR. A XCell4 Surelock Midi-Cell Electrophoresis System (Life 
Technologies, Carlsbad, CA, USA) was used for electrophoresis gels to ensure the IgG and 
Protein A were in native forms and not denatured. Purified water was sourced from a 
Millipore (Billercia, MA, USA) Milli-Q Direct 16 system, which after buffer preparation was 
filtered through 0.2µm vacuum filters to ensure sample purity and minimise contamination. 
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Buffers were sonicated for 15 minutes (Digitech Systems, Kolkata, India) to remove 
dissolved gas from solution. 
 
The XPR36 operates as described in Chapter 1. The chip is where the interactions take place 
on a thin gold surface coated with alginate with six “vertical” and six “horizontal” channels 
etched into the chip. Actually both flow directions are in the horizontal plane but flow 
channels are in sets of six, oriented at right angles to one another. The sets of channels are 
referred to, for convenience, as “vertical” ligand (L) channels and “horizontal” analyte (A) 
channels, due to their apparent orientation if viewed with the chip held up in front of the eye. 
The chip is maintained under a flowing solution while in the SPR, with a running buffer 
supply requiring frequent refill/replacement when running. There are two pumps (A and B) 
that allow for changing of running buffer during a run or additional capacity for extended 
runs. The sample chamber can either contain microplates with approximately 350µl wells or 
1.5ml sample vials but the instrument simultaneously draws up samples in sets of six (one per 
channel). The machine is shown below in Figure 4.1.    
 
 
Figure 4.1: The ProteOn XPR36. 1) The chip. 2) Sample chamber containing rack and autosampler.       
3) Running Buffer Chamber. 
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4.2 Buffer and Sample Preparation   
The most frequently used buffer was phosphate buffered saline with Tween-20 pH 7.4, which 
contains sodium chloride (137 mM), potassium chloride (3 mM), disodium hydrogen 
orthophosphate (10 mM), potassium dihydrogen orthophosphate (2 mM) and Tween-20 (a 
non-ionic detergent) at 0.005%. PBS is made to mimic physiological conditions with Tween-
20 added to improve SPR performance by reducing salt deposits. The PBST buffers used at 
pH 7.0, 6.5 and 6.0 were modified to improve buffer stability employing only sodium salts. 
Disodium hydrogen orthophosphate was used at 12.2, 6.3 and 2.46 mM, respectively, with 
sodium dihydrogen orthophosphate used at 7.8, 13.7 and 17.54 mM to maintain phosphate at 
20 mM. The sodium chloride and Tween-20 concentrations were the same as above in all 
buffers. All phosphate buffers were made up to the desired pH by the addition of 
hydrochloric acid and/or sodium hydroxide. 
 
Most of the other buffers were simpler in composition. The acetate buffers used were made to 
the desired concentration using sodium acetate with acetic acid and sodium hydroxide added 
to obtain the desired pH. When used as a running buffer in the SPR sodium chloride and 
Tween-20 were added as above. Similarly, the glycine-HCl, EDTA and MES buffers were 
made up from their named component with hydrochloric acid/sodium hydroxide added to 
reach the desired pH. The glycine-HCl was almost always made up with glycine at 10 mM, at 
pH 2.0, as it was used as the regeneration solution for the GLC chip. The imidazole, when not 
added to other buffers was simply made up to concentration in water. The EDAC and NHS 
were also made up in water.  
 
The IgG was made up from the lyophilized powder into stock solutions of >1 mg/ml in PBST 
(pH 7.4) for the initial experiments and then saline solution (137 mM) for the kinetic 
experiments so as not to affect the buffer significantly when mixed. The lyophilized IgG was 
stored at 4 ºC and the stock solutions were stored at -80 ºC in 750 or 1000 µl amounts. When 
used the stock IgG was stored at 4 ºC for no more than a week and never refrozen. The 
Protein A was always made up in PBST (pH 7.4), for stability, at concentrations between 0.1 
and 0.6 mg/ml. The stock solutions were stored at either -20 ºC or -80 ºC with the products 
(Sigma and Sino) both stored at -20 ºC. The Protein A was immobilised at such low 
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concentrations (<0.01 mg/ml) that the effect of the PBST buffer was negligible on the buffer 
used for immobilisation (MES or sodium acetate). Due to the minimal amounts of Protein A 
required the stock samples were used immediately and not stored or refrozen. When making 
up the stock solutions a microbalance was used to approximately measure the amount of 
powder before mixing up the solution. The solution was then centrifuged for 5 minutes at 
13,000 rpm and 4 ºC to separate insoluble components. The solution was then tested on the 
NanoDrop 1000 to get an accurate concentration. Solutions were centrifuged every day they 
were in use and concentration was tested when first defrosted. All products were tested using 
SDS-PAGE (in the XCEll4 Surelock Midi-Cell), in both native and reduced forms, to ensure 
they were intact and behaving as expected. All experiments performed on the XPR36 were 
temperature controlled with both the chip and the sample plates held at 25 ºC. 
 
4.3 Initial Experiments for the Determination of Optimal Parameters 
SPR devices are highly sensitive and to get the best results careful preparation of buffers and 
samples is crucial, along with rigorous testing to determine the best conditions for studying 
the interaction (e.g. ligand concentration, analyte concentration, buffer salt concentration, 
immobilisation method). The basic conditions and parameters are well established for 
chromatographic columns but these will not necessarily be perfectly reproducible or 
workable for an SPR and any deviations need to be noted to ensure the results remain valid to 
the large scale chromatographic processes.  
 
A range of chips, upon which the Protein A can be immobilised, are available for the XPR36 
with a variety of properties. Of the seven options (43) for the chip, high capacity varieties 
(HTE, GLM, GLH) can be immediately eliminated as reaction kinetics are more accurate at 
lower concentrations (26) because this limits aggregation of the analyte and ligand. Next, the 
LCP chip can be eliminated as it is for capturing lipid assemblies not proteins. That leaves the 
GLC, HTG and NLC chips, which immobilise the ligand by amine coupling, His-tag affinity 
and biotin affinity respectively. The HTG and NLC chips provide site-specific binding, 
giving a consistent ligand orientation but requiring the ligand to be altered for binding to 
occur. The GLC chip’s binding mechanism is not site-specific but gives randomly oriented 
ligands. Because the NLC and HTG chip offer similar advantages it was decided to 
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experiment with the HTG and GLC chips to determine the best option for the full 
experiments. 
 
The GLC chip was therefore tested first with a variety of concentrations of Protein A (10 to 
0.01 µg/ml) initially applied, based on molecular weight and previous experimentation. 
 
Pre-Conditioning: 
Before immobilisation was performed the chip was pre-conditioned by passing 0.5% SDS, 50 
mM sodium hydroxide and 100 mM hydrochloric acid solutions across the chip consecutively 
at 100 µl/min for 60 seconds. After eight blank/buffer (PBST) runs (to remove any residue), 
at 100 µl/min for 60 seconds, the chip can be immobilised. PBST was used because virtually 
all interactions between IgG and Protein A are carried out in PBS at a pH between 7.0 and 
8.0. 
 
Ligand Immobilisation: 
Immobilisation was performed according to the standard amine coupling protocol suggested 
by Bio-Rad. EDAC (133 mM) and NHS (33 mM) were mixed and applied to the chip to 
activate the surface and allow binding to occur at 30 µl/min for 300 seconds. The Protein A 
was then applied to the chip in a sodium acetate solution (10 mM, pH 4.0), at 30 µl/min for 
300 seconds, as acidic conditions are necessary for amine coupling to occur. Finally, any 
remaining active sites were blocked by the application of ethanolamine-HCl (1 M, pH 8.5) at 
30 µl/min for 300 seconds. Once more, eight buffer runs were performed to remove any 
residual chemicals. Once the immobilisation was complete IgG could be applied and the 
interaction was studied. 
 
HTG Chip Immobilisation: 
The immobilisation procedure for the HTG chip followed similar lines with a pre-
conditioning step to begin. The pre-conditioning was the same as for the GLC with the 
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addition of an EDTA (300 mM, pH 8.5) step after the original steps followed by the eight 
buffer runs. The HTG chip was activated by the application of nickel sulfate (10 mM) in 
MES buffer (10 mM, pH 6.0) at 30 µl/min for 120 seconds, with the Protein A following also 
in MES buffer at 30 µl/min for 300 seconds. The Protein A was applied at the same 
concentrations (10µg/ml and 5 µg/ml) as on the GLC chip. There was no deactivation step as 
the NiSO4 comes off naturally and small amounts of NiSO4 are not of great concern as the 
IgG does not have any histidine chains to cause significant interaction. The eight buffer runs 
are then carried out before the IgG interactions were initiated, to wash away any residual 
Protein A or NiSO4.  
 
Regeneration and Blanks: 
The interactions runs were separated by regeneration and blank runs to ensure they were 
consistent and did not affect each other. After each interaction step at least 180 seconds of 
regeneration occurred to ensure complete removal of any remaining IgG from the chip 
surface. These were followed by four to eight buffer runs comprising at least 480 µl of buffer 
over 480 seconds in total. These runs were to ensure uniformity of conditions between 
interactions by washing away any residues left by the previous steps.  These steps ensured the 
pH, salt concentration and ligand concentration remained as consistent as possible. If the 
buffer was changed a system flush was performed with the new buffer followed by four to 
eight buffer steps, the same as after an interaction. This did not change between the initial and 
kinetic experiments.   
 
For both chips, a number of initial runs were carried out with a variety of IgG concentrations 
(between 1 µM and 3 nM) to determine the best range of concentrations for clear and 
accurate results. Flow rate (25-200 µl/min limited by the XPR36), contact time (limited by 
the sample size) and dissociation time were also varied to examine any associated affects. 
PBST buffer (pH 7.4) was used as the blank and for the interaction between IgG and Protein 
A for the majority of the runs. Imidazole (10-30 mM) was added to the PBST for some of the 
runs on the HTG chip to decrease non-specific binding. The regeneration step was varied to 
determine the most effective regeneration buffer and showed some variation between chips 
with Glycine-HCl (10 mM, pH 2.0) and sodium acetate (10-100 mM, pH 2.0 and 3.0) used 
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for both and Imidazole (100 mM) and EDTA (300 mM, pH 8.5) used on the HTG chip only. 
These initial runs were useful in highlighting any issues with the chips or buffer conditions 
that they were performed under. Once complete these runs provided a clear picture as how to 
best perform the experiments for analysis and modelling.  
 
4.4 Kinetic Experiments 
From the initial experiments the best experimental parameters were found to provide the best 
data for analysis. The GLC chip was chosen as it was more robust and easiest to work with. 
The Protein A immobilisation was lowered by using dilute EDAC (13.3 mM) and NHS (3.3 
mM) and decreasing the concentration of Protein A to 1 and 0.5 µg/ml. Contact time between 
the IgG and Protein A was maximised by using the lowest flow rate (25 µl/min for 720 
seconds for the IgG) to provide the clearest picture of the interaction’s mechanisms. 
Dissociation time was set at 60 minutes to provide enough time for the dissociation rate to be 
clear. Glycine-HCl (10 mM, pH 2.0) was chosen as the regeneration solution because it 
provided the most effective elution, along with sodium acetate (10 mM, pH 2.0), and was the 
easiest to make up.  
 
After the baseline parameters were established as above, data could be gathered for analysis. 
To determine the effect of pH on the interaction it was decided to perform runs initially at pH 
7.4 and then from pH 7.0 down in steps of 0.5 to pH 3.0 (the frequently quoted elution point 
of IgG from Protein A), with additional experiments at closer intervals if required. At each 
pH, at least six interactions were performed to ensure consistency of results and that even 
multiple errors would not invalidate results. PBST was used from pH 7.4 to pH 6.0 with 
sodium acetate (20 mM) buffered with saline (after initial problems encountered with non-
specific interactions without saline) from pH 6.0 down to pH 3.0. Both buffers were used at 
pH 6.0 to ensure there was no significant effect when changing the buffer. For the six input 
samples a serial dilution of IgG was used (with the highest concentrations at 1.0667, 1.5, 3.0 
and 0.5 µM) for the first five samples with a blank buffer sample making up the final sample. 
In all cases an empty channel (either untouched or first activated with EDAC/NHS then 
deactivated with ethanolamine) was present on the chip, along with any bound channels to 
provide a reference, along with the blank sample, for comparison. The sensorgram for the 
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reference channel was subtracted from those for the ligand channels, to eliminate SPR 
responses caused by buffer change (changes in refractive index or some non-specific 
background interactions) rather than actual ligand-analyte interactions.  
 
4.5 Low pH Experiments 
Due to the elution of IgG from Protein A occurring between pH 3.0 and 4.0 it was impossible 
to attain consistent results at the lower pH values when the IgG was applied to the chip in the 
running buffer. To attain some data at the lower pH values, the IgG was first bound on in 
PBST at pH 7.4, then eluted under the desired (low pH) value. These experiments were 
expanded to all pH values to determine if the data collected was valid when compared with 
the data from the IgG binding in running buffer. These experiments were performed under 
the same conditions as those in running buffer.  
 
4.6 Data Analysis 
The data from the experiments was taken in raw form and processed using the Scrubber 
program described in Chapter 3. In all cases the baseline and injection time were aligned and 
any artefacts removed. However, the referencing varied between runs depending on what 
occurred during the run and what effect it had on the desired data. Some examples of this are 
when a channel or the blank sample was compromised and did not represent a true blank 
interaction. Alternatively, if the data was referenced against all three references (interspot, 
channel and sample) the slight variations that occured across each reference reduced the 
differences in the data to tiny amounts or add excessive noise. The processed data was then 
inserted into ClampXP for modelling using Langmuir equations. A variety of models were 
attempted to determine the nature of the interaction. Mass transfer and a simple 1:1 single site 
binding mechanism were ruled out because the curves did not fit with the data with the 
behaviours associated with these phenomena. This left multiple site and higher binding ratios 
to be worked through to determine the most accurate model. Aggregation was ignored as 
there was little evidence to suggest such a phenomenon was occurring and it would be 
difficult to quantify even if did (because of the constant flow of the IgG sample where it 
would be occurring).  
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Chapter 5: Results 
This chapter provides the collated data from the experiments with selected examples to 
illustrate the significant points. The full results, containing all runs used in the data sets, are 
shown in Appendix B. All of the data, except where mentioned, shown both here and in 
Appendix B was processed because few practical observations can be made from the raw 
data.                       
 
5.1 Initial Optimisation Results 
The initial results from the GLC chip were promising but obtaining the desired concentration 
of Protein A was challenging. The starting concentrations of 10 and 5 µg/ml of Protein A 
produced responses above 1000 RU during the IgG interactions. Even lowering the 
concentrations to 1 and 0.5 µg/ml produced responses above 500 RU, which remain higher 
than desirable due to aggregation and mass transfer becoming more likely at higher 
concentrations. The EDAC and NHS used in the immobilisation were then diluted 10 times to 
produce lower responses. Figure 5.1 shows what the initial results looked like after 
processing with the highest IgG concentration, reaching over 350 RU. While these results 
were significantly higher than the desired 200 RU they could still be modelled and they were 
clear and required little processing. It should be noted that this is a concentration of 0.5 µg/ml 
of immobilised Protein A with the IgG dilution series starting at 1.0667 µM (0.16 mg/ml). To 
bring the responses into the best range the concentrations were dropped to 0.1, and 0.05 or 
0.01 µg/ml.  
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Figure 5.1: An example of the data initially obtained from the GLC chip. Protein A immobilised at 0.5 
µg/ml and IgG injected at 160 µg/ml. 
 
The HTG chip was not so promising, with the basic protocol proving insufficient to produce 
clear results across a range of IgG concentrations. Non-specific interactions occurred across 
the chip when IgG was passed across as shown by Figure 5.2. The non-specific binding can 
be removed by referencing against a blank channel but difficulties remained in getting data 
that could be accurately modelled, as shown in Figure 5.3. This lead to the addition of 
imidazole to decrease non-specific binding, which met with mixed success. The 
concentration of imidazole required to fully reduce the non-specific binding depended on the 
concentration of IgG. Initially, 20 mM imidazole was used with 64 µg/ml of IgG and it was 
effective in reducing non-specific binding for the lower concentrations of IgG in the dilution 
series, but the highest two concentrations maintained some non-specific binding. However, at 
100 mM, imidazole is used to remove the Protein A from the chip, which suggests its use 
could be damaging to the Protein A even in small quantities. This was further reinforced by 
the rapid degradation ligand that was seen when using the HTG chip. In an attempt to reduce 
this degradation, the IgG was reduced to 2 µg/ml and the imidazole to 15 mM but problems 
remained even at such low concentrations. While there was some potential in using an HTG 
chip the results did not compare favourably with those attained from the GLC chip. 
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Figure 5.2: Non-specific binding of IgG across all channels on the HTG chip; only Flow cell 1 had Protein 
A immobilised on it.  
 
Figure 5.3: IgG-Protein A interaction on the HTG chip with 20 mM imidazole in PBST (pH7.4). A simple 
first order model was used because this best fitted the action. 
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The flow rate was varied to identify any mass transfer effects that could be occurring. Three 
flow rates were used, 25, 100 and 200 µl/min (the minimum, middle and maximum flow rates 
the XPR36 can achieve). Each was run using a 250 µl sample for 600, 150 and 75 seconds 
respectively. The combined runs can be seen in Figure 5.4, following the same adsorption 
line at all flow rates. Each flow rate was tested three times for consistency and any 
combination produced would look like Figure 5.4.  This suggests that there were no mass 
transfer effects and the process is not limited by any factors other than the interaction itself, 
as desired.  
 
Figure 5.4: Three different flow rates of IgG interacting with Protein A in uniform conditions. 
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5.2 Kinetic Experiment Results 
A number of different models were tested against the data to determine the most accurate and 
robust model. Mass transfer was ruled out as shown above and a simple 1:1 model does not 
curve in the way these data do. Models were then tested by steadily adding complexity until 
an adequate fit could be found. A 2:1 binding ratio was then attempted as this seemed likely 
given Protein A’s ability to bind two IgG, an example of this is shown in Figure 5.5. Next a 
single-binding two-site model was tested, with mixed results as shown in Figures 5.6 and 5.7. 
A three-site single binding model was also tested, shown in Figures 5.8 and 5.9 for 
comparison with Figures 5.6 and 5.7. Finally a two-site, double-binding (2:1 IgG:Protein A) 
model was tested, shown in Figure 5.10. This model was harder to fit (hence the different 
data set) as ClampXP finds the additional complexity unnecessary and stops fitting until the 
parameter is removed. No further models were tested, as it became clear that further 
complexity did not improve the fit of the model. The three-site single-binding model was 
chosen to go forward with, as it was robust and effective at modelling the large amount of 
data gathered. 
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Figure 5.5: A 2:1 binding ratio (IgG:Protein A) model, single site. Red is the model, black the data. 
 
Figure 5.6: A good two-site (on the Protein A) model with single-binding. Red is the model, black the 
data.  
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Figure 5.7: Another two-site model but not as accurate as in Figure 5.6. Red is the model, black is the 
data. 
 
Figure 5.8: Three-site, single-binding model using the same data as Figure 5.5. Red is the model, black is 
the data. 
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Figure 5.9: The three-site model, single-binding, using the same data as Figure 5.6. Red is the model, 
black is the data. 
 
Figure 5.10: Two-site, dual-binding model. Red is the model, black is the data.  
55 
 
 
Once the model was established and the data collected and collated, the larger scale analysis 
of trends across the pH range could be examined. Unfortunately, below pH 5.0 it became 
extremely difficult to determine interaction kinetics because the IgG was strongly interacting 
with the chip surface and the Protein A and IgG interaction was weakened. At pH 5.0 and 
above a large amount of data was obtained and analysed. Figures 5.11, 5.12 and 5.13 show 
the association, dissociation and rate (association over dissociation) constants obtained from 
the experiments between pH 5.0 and 7.4. The averages of these can be seen in Figures 5.14 to 
5.16, which make the overall trends somewhat easier to see. The association and dissociation 
rates show a downward trend from pH 7.4 to 5.0, however the rate constants remain relatively 
steady.  
 
Figure 5.11: Association/adsorption constant for IgG-Protein A interactions in running buffer. ka1 is the 
highest and ka3 the smallest in the set of three constants obtained from each interaction. 
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Figure 5.12: Dissociation constant for IgG-Protein A interactions in running buffer. kd1, kd2 and kd3 are 
the dissociation rates that go with ka1, ka2 and ka3 respectively. 
    
Figure 5.13: Rate constants for IgG-Protein A interactions in running buffer. K1, K2 and K3 represent 
ka1, ka2 and ka3 respectively.  
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Figure 5.14: Average of all the association constants in each separate run and each pH. 
 
 
Figure 5.15: Average of all dissociation constants in each separate run and each pH. 
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Figure 5.16: Average of all rate constants for each separate run and each pH. 
 
5.3 Immunoglobulin G Binding in PBST 
The difficulty of measuring pH less than 5 with the IgG in running buffer forced a rethink of 
how to measure the rates at low pHs. Because the binding phase is not as important at these 
levels (in practice, binding would not be expected at this pH so purificaition would be run at a 
pH value closer to neutral), the focus was moved to the elution phase, only, at low pH, while 
PBST (pH 7.4) was used to bind the IgG. Even with this strategy it was difficult to obtain 
consistent results below pH 4.0. IgG in PBST (pH 7.4) was used across the full range of pH 
to provide a basis for comparison with the IgG in buffer experiments. Figures 5.17 to 5.19 
show the association, dissociation and rate constants respectively, for the experiments. While 
the association constant is not of any real purpose it is shown as it was used in the model 
because it affects the dissociation constant. The average values of each constant are also 
shown in Figures 5.20 to 5.22 to see what overall trends exist. The trends shown are 
somewhat similar to those of the IgG in buffer, with a slight decline from pH 6.5 to 5.0 for 
the dissociation rates. Below pH 5.0 a steady increase in dissociation constants occurs. 
However, the rate constants remain relatively steady between pH 5.0 and 7.0, but show a 
steady decline from pH 5.0 down to 3.0. This is in line with expectations of decreasing 
affinity as pH decreases. 
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Figure 5.17: Dissociation constants for IgG-Protein A interactions binding in PBST (pH 7.4). kd1, kd2 
and kd3 are the dissociation rates that go with ka1, ka2 and ka3 respectively. 
 
 
Figure 5.18: Rate Constants for IgG-Protein A interactions binding in PBST (pH 7.4). K1, K2 and K3 
represent ka1, ka2 and ka3 respectively. 
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Figure 5.19: Average of dissociation constants per run and pH for IgG in PBST (pH7.4).  
 
 
Figure 5.20: Average of rate constants per run and pH for IgG in PBST (pH 7.4). 
 
The behaviour of the IgG-Protein A interaction changes significantly below pH 5.0, as 
demonstrated by the difficulty producing results when attempting the reaction in buffer. The 
difference between the buffer and IgG in PBST (pH 7.4) is stark and produces inflated values 
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from the model to cope with the two different parts of the interaction, as shown in Figures 
5.23 to 5.26. As the pH descends the model struggles to accurately reproduce the association 
phase because of the fast dissociation that occurs once the injection is finished (Figures 5.25 
and 5.26, especially). These graphs show that a significant portion of the IgG dissociates 
quickly at pH 4.5 and the fraction that remains bound decreases with the pH. This largely fits 
with what is expected given a previous study (33) found IgG2 elutes at around pH 4.0 and 
IgG1 follows at pH 3.0. 
 
Figure 5.21: Protein A-IgG interaction at pH 4.5 with IgG in PBST at pH 7.4. Data is black, model is red. 
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Figure 5.22: Protein A-IgG interaction at pH 4.0 with IgG in PBST at pH 7.4. Data is black, model is red. 
 
Figure 5.23: Protein A-IgG interaction at pH 3.5 with IgG in PBST at pH 7.4. Data is black, model is red. 
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Figure 5.24: A-IgG interaction at pH 3.0 with IgG in PBST at pH 7.4. Data is black, model is red. 
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Chapter 6: Discussion 
Many problems and challenges were encountered throughout with a variety of solutions 
attempted, with varying success. Whether the solutions used were appropriate and, with the 
benefit of hindsight, whether better options existed will be discussed here. The validity of all 
methods and results will also be examined to determine what can be taken from this study.  
 
6.1 HTG Chip Immobilisation and Interactions 
As mentioned in the results the HTG chip produced high non-specific binding (Figure 5.2) 
when the IgG was interacted with the Protein A, which seemed to affect the accuracy of the 
data obtained. This led to the HTG chip being discarded for any further experimentation, as 
the GLC chip gave much better responses without significant alteration to the chip 
conditions. However, Bio-Rad has performed Protein A-IgG interactions on a His-tag chip 
with some success (44). This leads to questions about how each study was performed and the 
results between the two were dramatically different. 
 
The method of immobilisation of the Protein A is important for this comparison, because this 
could immediately produce significant differences between this project and Bio-Rad’s work. 
Both studies immobilised Protein A over 300 seconds onto the chip, which gave a response of 
roughly 2500 RU. Not only that, but the conditioning and activation steps were also identical 
in both studies. Furthermore, when the experiments did not produce the desired results the 
ligand was re-immobilised to try and increase the interaction effect, and make it 
distinguishable from the non-specific binding. The uniformity between the two studies 
suggests that the difference in achieving clear results was not due to the immobilisation 
procedure. This leaves the interaction conditions as the likely cause of the disparity. 
 
The interaction conditions were also close to uniform between the two, with PBST (pH 7.4) 
used as the running buffer in both cases. Bio-Rad’s results are near perfect in terms of 
behaviour, whereas, in our hands, interaction failed to line up with the expected behaviour 
over a dilution series. This suggests that the sample preparation was potentially poor as that 
would cause the concentrations to be inexact and not fit the prediction. However, the 
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problems persisted over a number of runs using different samples, which makes the 
consistency of such an error less likely, though still possible. Also given that these errors 
were not an issue when subsequently using the GLC chip, sample preparation errors are less 
likely. This does potentially suggest a fault in the chip. Another potential factor is the 
regeneration solution used, as this was not fully determined on the HTG chip at the time of 
this work. Bio-Rad used 50 mM NaOH as their regeneration solution, while this project 
tested a variety of solutions for regeneration, with a focus on low pH, as this was effective for 
elution in chromatography and on the GLC chip. However, all regeneration solutions were at 
least pH 3.0, which was shown in the results as leading to almost complete elution within 
seconds, with at most 10% of the IgG remaining bound. While this might have had some 
effect, it should not have been significant, especially because none of the interactions showed 
saturation had occurred and any remaining IgG would be included in the baseline when a new 
run was performed. This also would not explain the poor results of the first run after 
initialisation. 
 
The addition of imidazole to the buffer was not performed by Bio-Rad but it is a 
recommended method for reducing non-specific interactions on the HTG chip. The imidazole 
had the desired effect for the most part but, as noted, did not remove all of the non-specific 
interactions at higher concentrations of IgG. Despite this improvement, the same problems 
with the processed data remained. Adding imidazole also raised other questions, given its 
properties and how these are used. The first question is whether the imidazole affects the 
IgG-Protein A interaction as well as the non-specific interactions and if so, how significant is 
that effect? The second question, which has already been mentioned, is what effects the 
imidazole has on the immobilised Protein A, given its use for stripping ligands from the HTG 
chip? To answer these questions a great deal of testing would need to be undertaken, which 
seemed non-productive when the simple alternative of using the GLC chip was available. 
Ultimately, resolving the problems with the HTG chip were abandoned because the GLC chip 
already met the requirements of the experiments. It appears that the random orientation of the 
Protein A had no significant drawbacks. (Further information was sought on the experimental 
procedures used for (44) by direct contact with the original authors but none was provided.) 
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6.2 Models  
The three-site single-binding model was chosen to model the entire result set because it 
produced good fits and was robust across the majority of the data. However, it should be 
noted that for a number of models ClampXP found the third site unnecessary and a two-site 
model was used instead. The model does not necessarily identify the true nature of the 
interaction but, along with the existing literature, the nature of the interaction is further 
elucidated. A site directed binding of the Protein A to the chip could perhaps help improve 
the understanding of the mechanisms of the interaction, because this would eliminate any 
effects caused by the polymer layer interfering with the binding. 
 
Protein A contains five Fc binding sites that are largely similar in terms of structure but the 
way in which the larger structure of Protein A affects this is unknown. There also exists the 
ability for Protein A to interact with the Fab region, although this interaction is much weaker 
(16, 17). Just one of the five interaction sites with IgG has been studied (30) and that 
interaction was studied in isolation (i.e. using only a fragment of Protein A). This leaves the 
exact binding mechanisms largely unknown. It is well known that each Protein A molecule 
can bind two IgG molecules (18), which provides one limitation on the binding mechanism. 
Given the structural similarities of the five sites (13) it seems probable that the binding 
mechanisms of each are also similar and perhaps could even be expressed as uniform in terms 
of the reaction constants. This project suggests this is not the case, because the binding is too 
complex to be expressed even as a double-binding single-site model. However, given that 
five sites exist and potentially just two need to be expressed in a model, there does seem to be 
some evidence that the five sites share similarities. There is also the possibility that the sites 
work in groups of two and/or three to form two binding sites for the IgG. If the Protein A 
does act as a two-site double-binder, then there are steric effects to consider that could affect 
the binding of the second IgG. These factors must be applied when considering each model 
and its likely representation of the IgG-Protein A interaction. 
 
The three site single binding model can be explained in a number of ways that fit with the 
existing knowledge. The first and simplest explanation is that the Protein A contains three 
different binding sites that can individually bind one IgG, which prevents the other sites from 
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binding IgG likely due to the random orientation of the Protein A on the chip or the short 
duration of the contact time. The second explanation is that again there are three sites but 
double binding can occur, however the three sites are independent of one another and the 
addition of double binding equations or parameters is unnecessary. The third explanation is 
that there are only two sites, but double binding can occur and the second binding is affected 
by the first and a third parameter set compensates for this effect. Other explanations of 
greater complexity could undoubtedly be put forward, but these four simple explanations give 
reasonable scope and further complexity, without added accuracy, is undesirable in the 
model. Of these explanations no one possibility seems particularly more likely than any 
other. There are almost certainly two sites and a third effect exists that needs to be accounted 
for. This seems likely because the two site model fits the data with a good level of accuracy 
but the model can still be improved upon. What the exact nature of the third effect is harder 
to identify as a significant number of possibilities exist and it could be a single effect or a 
combination of many. 
 
A single site binding model, regardless of the number of IgG that can be bound, does not 
adequately account for the behaviour the interaction produces. A single site single binding 
model can be applied when the interaction period is short and the IgG concentration is 
significantly lower than the Protein A concentration as demonstrated by Bio-Rad (44). This is 
likely because of the dominance of the higher affinity site over the shorter time periods and in 
greater availability. Single binding models do not work at higher binding numbers because 
the first IgG bound must be the last to elute, which forces the first binding to have a low 
dissociation to match the interaction behaviour in the elution stage. This low dissociation 
limits how large the first association constant can be to bind the right amount of IgG for the 
elution stage. This causes the model to rise too slowly in the association phase; hence the 
model cannot match the data in both the association and elution phases. Ultimately, this 
prevents any single site model from being accurate and forces the introduction of additional 
binding sites. 
 
Models with greater complexity than the three site single binding did not significantly 
increase the accuracy of the model and were discarded. When modelling any system the aim 
is to produce a model of sufficient accuracy and the least complexity for a number of reasons. 
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Low complexity makes models faster to simulate and easier to understand for users. Added 
complexity for minor increases in accuracy can lead to models that are affected by data noise 
or minor factors that lead to erroneous conclusions about the data’s behaviour. For some of 
the data sets the higher order models show increases in model accuracy but are unnecessary 
for the majority of the data. This gives a clear indication that the additional parameters do not 
give a true representation of the interaction’s mechanism. The one higher order model that 
may accurately represent the interaction is the two-site double-binding model. As discussed 
the two sites could be largely independent of each other causing only minor steric hindrance 
to the second binding. Due to the minor nature of the hindrance it could be adequately 
represented by a single parameter set (the third site) when the true action is present at both 
sites. While this is possible, without knowing with certainty that it is occurring there is no 
point representing it and even if it is occurring it is accounted for in some manner. 
 
6.3 Experimental Conditions 
The conditions under which the experiments were performed had significant effects on the 
results that were produced. This is particularly obvious in the case of binding in sodium 
acetate buffer, where the addition of saline significantly decreased non-specific interactions 
enough to allow for proper interpretation of the results. A variety of other conditions affect 
the interaction and the subsequent data obtained and for that reason must be carefully 
controlled to ensure the validity of the results.  
 
As mentioned previously, temperature affects the rate of reaction as described by the 
Arrhenius equation, making it imperative to be controlled to ensure consistent data. To 
remove the need to calculate the effect of the temperature all experiments were performed at 
25 ºC. This temperature was chosen as Protein A chromatography is generally performed at 
room temperature as there seems to be no significant benefit to performing it at any higher or 
lower temperature, although above approximately 40 ºC degradation of IgG occurs. Given 
that the IgG-Protein A interaction usually occurs at body temperature it is possible that the 
interaction would be stronger/faster at those conditions than at room temperature but no 
published study has been done to validate this hypothesis. Given the affinity of IgG and 
Protein A at room temperature, it has not been necessary to try and increase the affinity and, 
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because heating/cooling of chromatographic equipment can be costly and difficult, the 
interaction temperature has not warranted investigation. 
 
The buffer makeup produced significant effects in the experiments and was one of the most 
difficult experimental conditions to optimise.  The choice of buffer was based on those used 
previously in the literature with PBS being used almost universally for the interaction 
between pH 7.0 and 8.0, it was the obvious choice for the higher pH buffers. For the lower 
pHs a number of different buffers had been used with the most common being glycine-HCl, 
acetate and citrate buffers. There has been no significant comparative study of buffer effects 
either on binding or elution, with the only studies to have any kind of buffer focus being 
those comparing citrate buffers with and without arginine (38, 40). There is also some older 
work on the use of magnesium chloride in buffers to improve elution (45) but this is not 
commonly used in more recent times. Sodium acetate was arbitrarily chosen from the more 
common lower pH buffers and for the initial testing. Once the non-specific binding was dealt 
with by the addition of saline to the buffer, acetate buffer performed effectively enough that 
no further consideration was given to the buffer use, until the kinetic and low pH experiments 
were complete. Both PBST and acetate buffers were used at pH 6.0 (see Appendix B) to see 
if there was any significant effect caused by the change but none were observed. 
  
The binding time was relatively simple to optimise but bears analysis to ensure the 
experiments validity and provide guidance for any future work. The binding time is of 
interest because duration can significantly affect the behaviour of the binding. Bio-Rad (44) 
created data that could be modelled as a simple first-order interaction by using an abundance 
of immobilised Protein A and a short interaction time (90 seconds). The current work, 
however, produced data that was definitely not a first order interaction by limiting the Protein 
A and using extended interaction times (600 seconds). This study is seeking to provide 
knowledge for Protein A chromatography in industry and thus must match those conditions 
as far as possible. The most efficient use of any chromatography column is for binding to last 
until breakthrough of [usually] 10% of the desired compound occurs, to ensure the column is 
efficiently used and to minimise the number of runs needed for a full batch to be processed or 
to minimise the size (and cost) of column required. As noted above (in Chapter 2), the 
minimum residence time for IgG in a Protein A column is two minutes for effective binding 
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to take place and, generally, multiple column volumes of sample will be passed through 
before breakthrough occurs. This suggests that at an absolute minimum, a two-minute 
interaction is required, with longer times better representing the whole process. Given that 
columns are generally saturated this also requires time for the majority of the Protein A sites 
to be saturated with IgG, which also requires longer time periods on the SPR or high 
concentrations of IgG compared with Protein A. It is difficult to model an entire column 
because the interactions will be different through the length of the column and these will also 
change with time, however, it is possible to replicate a single section. The binding time was 
limited by the SPR control software and hardware, with the injection limited to 400 µl (14 
minutes injection time) by the software and 275 µl (11 minutes injection time) by the wells 
on the micro-plate. To prevent any air in the SPR, 10 minutes (600 seconds) was chosen as 
the binding time.   
 
The elution time was also important for providing an effective analogue to a chromatography 
column. Instead of trying to exactly replicate the elution time needed through a column the 
elution time was optimised with the goal of having steady elution at the end of the time so 
any required extrapolation would be simple. The easiest way to achieve this was to use a 
relatively long elution time to ensure that any weak binding had already eluted and only the 
stronger bindings remained. An hour was chosen as the elution time after some 
experimentation, as this provided more than enough time for the weak non-specific 
interactions to elute and the stronger binding (and, hence, more slowly eluting) molecules to 
dominate the action. Half an hour would probably have been sufficient but there was no large 
detriment to a longer elution time, while the data from the longer elution can be decreased to 
provide data for a shorter elution time if that is so desired in the model. 
 
6.4 Kinetic Experiments 
The models for the kinetic experiments show a number of trends within each pH set and 
across the pH range. The limited pH range that these experiments were able to be reliably 
performed in limits what can be taken from the experiments, but a number of behaviours 
remain of interest for further assessment. The three interaction constants give some 
indications of how the interaction occurs and how this changes with the pH. 
71 
 
 
One noticeable feature of the interaction constants is that the highest association constants, 
and their dissociation constants (also the highest), have the lowest (generally) rate constant of 
the three constants. The largest constants generally make up the third site with the first two, 
largely resembling the constants attained when using a two-site model. The behaviour of the 
third site is mostly caused by the model needing to account for the sharp rise during the 
association stage and sharp drop off at the start of the dissociation stage that is not fully 
characterised by the other two sites. This explains why the third site has the lowest rate 
constant, as it is accounting for the smallest part of the data’s behaviour. The third site had 
consistently the highest error of the three sites (see Appendix B), which is likely due to the 
small influence it has on the overall model and hence the least precision is needed to create 
its effect. 
 
Over the pH range (5.0 to 7.4) a number of trends are apparent from the interaction constants. 
The rate constants remain roughly constant, averaging between 1x107 and 1x108 as shown in 
Figure 5.16. This suggests that the interaction is not significantly affected by pH in this range. 
This fits with results from previous studies that found the elution points of the IgG subclasses 
to be between pH 5.0 and pH 3.0, with IgG1 mostly eluting at pH 4.1, while IgG2 eluted at 
first at pH 4.9 and again at pH 3.5 (33). This suggests that binding is at least retained until pH 
4.0 and therefore it is likely that the interaction will continue to occur until the pH nears this 
point, with the possibility of the interaction continuing past this point only for IgG1. The 
dissociation and association constants do show some variation over this pH range with a 
significant drop in the average between pH 6.0 and 5.5. This drop is largely due to the 
decrease in the third site rate constant mentioned above. However, the drop is consistent 
between the two constants, causing it to have little effect on the rate constant. This change 
indicates that the curve becomes smoother after pH 6.0 because the association and 
dissociation is slower. This smoothing of the curve suggests that the saturation point is being 
approached (but some weaker interactions are continuing) at both pH values but it is achieved 
faster at the higher pH.   
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There were a number of difficulties when trying to produce consistent results below pH 5.0 
with the IgG in running buffer. An overwhelming amount of non-specific binding occurred 
below pH 5.0, masking the Protein A-IgG interaction. This is likely caused by the alginate 
layer of the chip becoming charged, as this is the pH range used for immobilisation. These 
interactions still occurred even on a channel that was first activated with EDAC and NHS, 
before being deactivated with ethanolamine-HCl, which implies that the interactions cannot 
be completely removed through pre-treatment of the chip. A potential solution to this 
problem would be to increase the sodium chloride concentration, as this proved effective 
when non-specific binding occurred when the buffer was changed from PBST (pH 6.0) to 
sodium acetate (pH 6.0). Higher salt concentrations could have an impact on the interaction 
but the results would still give some idea of the behaviour of the interaction at lower pH. 
Additionally, the IgG starts to degrade at lower pH, leading to an increased number of 
artefacts breaking up the interaction data. The only way to combat this degradation would be 
to minimise the time the IgG spends in the buffer by preparing samples immediately before 
injection across the chip. Instead of dealing with these problems the decision was taken to 
inject the IgG in PBST (pH 7.4) to study the dissociation, which admittedly compromises the 
association values attained from such experiments. This new method was applied across the 
full pH range desired (3.0-7.4) to see what effect this had on the interaction constants when 
compared with those applied in buffer. 
 
6.5 Low-pH Experiments 
This set of experiments bears a great deal of similarity to the chromatographic purification of 
IgG using Protein A media. The application of IgG was performed in PBST at pH 7.4 to 
ensure effective binding, which was followed by elution using the desired buffer at a lower 
pH. This method was used because it was based on the behaviour of the system that this study 
seeks to help elucidate fully. This approach does make the modelling of the data more 
difficult, due to the two conditions used, as well as making the results less useful in 
predicting overall behaviour. Despite those reservations, some useful observations can still be 
drawn in regard to the dynamic of the elution over the pH range. 
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The interaction constants show behaviour that at first appears somewhat unusual but upon 
closer inspection larger fits with the expected behaviour as the pH decreases. Figure 5.18 and 
5.20 show how the rate constants change with the pH, showing a steady decreased from pH 
5.5 down to pH 3.0. This decrease is expected as the pH drops the binding should get weaker 
and elution should occur faster. Oddly, the rate constants increase as pH decreases from pH 
7.0 to 5.5, which may be due to the need for the association constant (not shown because the 
binding occurs at pH 7.4 and the values are not a true representation of the mechanism) to 
increase more than the dissociation constant increases in order to maintain the same amount 
of IgG bound in the association stage. This effect may only be present from pH 7.0 to 5.5, 
because below this point the running buffer may start affecting the binding, because of 
sample/buffer contamination caused by mixing in the SPR or residue on the chip. From pH 
4.5 down, a steady increase in the dissociation constants occur as the IgG more rapidly 
dissociates from the Protein A. At pH 7.0 the rate constant seems in line with the overall 
trends, but the dissociation constants are significantly lower than the next data set. These 
results were the last obtained and the data had some problems (see Appendix B) that may 
have been caused by chip degradation. Only two runs were at pH 7.0 were included as the 
other six runs data was too flawed for modelling.  
 
The first basis for comparison is between previously reported elution points and the 
behaviour observed in these experiments. Figures 5.21 to 5.24 show the behaviour of the IgG 
when exposed to pH 4.5 to pH 3.0. At pH 4.5 approximately 40% of the IgG remains bound 
after 10 minutes of elution, which decreases to 30% at pH 4.0. At pH 3.5 and 3.0 elution 
speeds up considerably with just 13% and 10% left after one minute of elution. The literature 
suggests that IgG elutes between pH 5.0 and pH 3.0 (33), which fits with these observations. 
The difference between pH 3.5 and 3.0 is small in terms of remaining IgG but in a full scale 
chromatography column there may be benefits to using the lower pH, such as sharper elution 
peaks and the dilution of the elution buffer, from mixing with the residual binding buffer, 
would not affect elution greatly. Of the three binding sites used in the models there was clear 
variation in their association/dissociation constants with one site binding much stronger 
(having the lowest dissociation constant) than the others. This site was the only one to retain 
the IgG for any significant period during elution as expected from the earlier experiments.   
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The next comparison is between the interaction constants of these experiments and the 
previous kinetic experiments. Looking at the rate constant averages between pH 5.0 and 7.0 
(Figures 5.16 and 5.20) for both forms of interaction they are roughly consistent with both 
having a pH average between 1x107 and 1x108 excepting the IgG in PBST at pH 5.5 which is 
slightly larger. However, the buffer experiments are more consistent between pH values, 
whereas the IgG in PBST values seem to peak at pH 5.5 and fall away either side of this 
point. This variation is minor and the likely causes were discussed above. The dissociation 
constants do not show such uniformity between the two experimental forms, which can be 
seen in Figures 5.15 and 5.19. The dissociation constants averages for the kinetic experiments 
show a step change between pH 6.0 and 5.5 with the other values consistent above and below 
this point. The averages for the IgG in PBST experiments, on the other hand, show a steady 
downward slope from pH 6.5 to 5.0 (the outlying point at pH 7.0 was discussed previously). 
The dissociation constants behaviour in the kinetic experiments averaged between 100 and 
1000 between pH 7.0 and 6.0, which then drops to 0.01 for pH 5.5 and pH 5.0. The IgG in 
PBST experiments have larger numbers trending down, from over 1000 to 10, between pH 
6.5 and 5.0. This consistency is explained by the higher association constants that the low-pH 
experiments produced (Appendix B), causing behaviour of the rate constants in the two 
experiment sets to be similar, with the higher values in the IgG in PBST largely cancelling 
each other out. Based on these comparisons, and the previous analysis of the kinetic data, it is 
clear that in the pH range of 5.0 to 7.0 there are only minor effects on the interaction, mostly 
relating to association and dissociation speed. It is possible that lower concentrations of IgG 
would further elucidate the effect of pH in this range as slowing the interaction could prevent 
binding saturation.  
 
  
 
 
  
75 
 
Chapter 7: Conclusions 
This project has provided some insights into the binding properties of Protein A and IgG but 
there is still a great deal that remains to do. Given the importance of IgG in treating a variety 
of diseases and the crucial role that Protein A affinity chromatography plays in the 
purification process it is surprising that this area has not be studied previously in any depth. 
The interaction possesses complexity with the six different binding sites on the Protein A 
(five for the Fc section and one for the Fab section) and a proven binding ratio of 2:1 IgG to 
Protein A. However, the models produced from the data in this thesis are not overly complex 
with a two-site model proving adequate for most of the data, with a third site being desirable 
for greater accuracy. Ultimately, the interaction between the two molecules proved less 
challenging to interpret than experimentally producing accurate data below pH 5.0 did. 
 
The data and models produced from the experiments fit with the results from previous 
studies, while also providing further insights into the exact nature of the interaction. At pH 
5.0 to 7.4 the Protein A and IgG have a strong interaction that dissociates very slowly, while 
some weaker interactions are clearly present as well. A number of explanations exist that 
match this behaviour, such as the Fab binding site, which has been noted as comparatively 
weak in previous studies, and steric inhibition causing weaker binding, highly likely due to 
IgG being three times the size of Protein A. Below pH 5.0, more significant elution begins to 
occur and rapidly accelerate as the pH descending to almost instant elution of almost 90% of 
the IgG at pH 3.5. This is in line with previous studies that found similar elution behaviour 
using pH gradients. The data and models potentially have applications for modelling a 
chromatographic system although the scale up would be challenging and additional factors, 
such as mass transfer effects, would need to be taken into account.  
 
A number of areas warrant further investigation, that were not addressed by this project, in 
order for the binding kinetics to be fully understood. The interaction below pH 5.0 is the first 
place to start with a number of options existing for further attempts. The first option is a 
change of platform away from SPR so that the non-specific interactions will no longer be a 
problem, although few systems exist that can so easily record real time interactions in a 
similar manner to SPR. If the SPR is persevered with, then an increase in saline concentration 
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is a potential solution, given the effect it had in this project. A change of chip is also an 
option, although given the difficulties experienced with the HTG chip, it seems an unlikely 
solution. If saline is increased then some consideration must be given to the salt effects on the 
interaction, and a study of different salts and their concentrations should be considered. Salt 
effects remain mostly unexplored and warrant further investigation regardless of the use of 
saline. This study seems unique at this point in time and attempts at replication could prove 
useful in dealing with problems, investigating various effects and confirming or refuting the 
data and models that have been produced.        
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Chapter 8: Recommendations 
This project has highlighted many areas for future work with the following areas of most 
promise: 
- Attempt low pH (<5.0) runs in running buffer with higher sodium chloride 
concentrations to try and combat the non-specific binding that occurs.  
- A comparison between buffers made up of different salts should be performed. 
This initially could be done at a small selection of pH with further work occurring 
in areas of interest. 
- A comparison between buffer concentrations could also be performed in a similar 
manner. 
- Use the models from this project to create a larger scale model for 
chromatography columns in order to optimise elution conditions.  
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Appendix A: Sample Models 
The models were discussed briefly in Chapter 3 but require further explanation in order to 
recreate them and/or determine their accuracy. The ProteOn Manager software is self-
explanatory and easy to use and does not require further explanation in order for the models 
used in this thesis to be recreated. Scrubber is also simple to use, and as it was not used to 
model the data, will not be further explained. Stella and Excel will be the focus of this section 
due to their more challenging nature, with ClampXP also being expanded upon to a less 
extent. 
 
Stella uses more visual models as shown in Figure 3.4 (and again in Figure A.1) with the 
equations operating in the background. The best way to describe the machinations of Stella is 
to explain how this model (Figure A.1) works. The thick blue arrows represent physical 
changes, while the thin pink arrows represent an influence/part of an equation. Beginning at 
the left side of the figure are the injection time and feed concentration of IgG (Cfeed), these 
are simple parameters set by the user. These parameters determine the value of the bulk 
concentration of the IgG in solution, being equal to the feed concentration for the duration of 
the injection, and then being set to zero after the injection period has finished. The “Free 
Ligand” (Protein A), “Ligand Site A” (IgG bound to Protein A only at the first site) and 
“Ligand Site B” (IgG bound to Protein A only at the second site) boxes all represent the 
concentration/reservoir of their components. The free ligand is set initially to the 
concentration of the Protein A on the chip, approximated from the response created by IgG 
binding that occurred during the experiments. The two binding sites are set to zero initially as 
no IgG has been bound. During the interaction the free ligand reacts with the IgG in bulk 
solution along the two pathways to form one of the bound complexes. The “Association A” 
and “Association B” circles represent the association reaction and are here set to Langmuir 
equations. These equations are affected by the association constants shown as “kaA” and 
“kaB” circles. Similarly, the dissociation pathways are shown with the appropriate equations 
and parameters. The no name equations represent the association and dissociation reactions 
for the bivalent/dual-binding of Protein A and IgG. The dashed line circles with parameter 
names represent the exact parameters named but are ghosts to provide model clarity. A steric 
inhibition factor was also used for the bivalent binding, as shown. The concentrations of each 
contribute to the total bound and RU circles that represent the output variables of the model.  
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Figure A.1: The Stella model from Figure 3.4 reproduced for ease of use. 
 
Stella runs all these equations and variables as finite difference equations based on a user-
defined time step. The variables produced can be displayed as a table and/or a graph. One 
advantage of Stella is that any variable can be easily tracked by setting up the appropriate 
output variable in the model. The great disadvantage of Stella, as mentioned in Chapter 3, is 
that it does not possess any optimisation algorithms, so any data modelling must be optimised 
by the user, which is a slow process for the large data sets produced by the SPR. 
 
Excel was set up to use Langmuir equations in a finite difference model in a similar manner 
to Stella. Figure A.2 shows a screen shot of part of an excel model; on the left is the 
experimental data, with the model on the right. Above the model, the parameters and their 
values are listed, while the IgG concentration (molar) and injection start and stop times 
(seconds) are above the data. The model shown is a dual-binding single-site model, hence, 
only two sets of rate constants. The time displayed shows that a measurement is taken every 
0.9 seconds, which is used as the time step in the model. Langmuir equations are used with 
each value being determined based on the concentrations from the previous step. A squared 
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error is easily introduced by simply adding a column to the right of RU that takes the model 
value minus the data value squared to get the error. The solver function can then be used to 
minimise the sum of the errors by varying the model parameters to optimise the model. The 
data can be represented as a graph simply by using the graph function in Excel. While Excel 
is highly versatile it does require a great deal of time because of the control it affords. An 
example of this is the identification of the injection points and altering of the model equations 
at these points to account for the change in conditions. When these tasks have to be repeated 
five times per run (as the times are not perfectly aligned across all the data sets), for over one 
hundred runs this can become extremely time consuming and a faster program becomes 
desirable. 
 
Figure A.2: Screen shot of an Excel model. 
 
ClampXP again uses finite difference models employing Langmuir equations to model the 
experimental data. Figures A.3 and A.4 show the input tabs of Clamp and the parameters set 
by the user. In Figure A.3 every compound/molecule of the interaction is listed, this 
particular model is using a two-site, dual-binding model. The IgG has been set as injected 
(“Inj” tick box), while the Protein A is set as the ligand/local (“Lcl” tick box), with the 
remaining IgG-Protein A complexes having their initial concentration set at zero. The 
Vers 3.5b Data Pro A conc 26 uM
Conc1 6.67E-08 Model
Start1 0 ka1 20000 ka2 30000
Stop1 2855.3 kd1 0.00005 kd2 0.009
Injn 1
Cell 3
Time7 Data7 PA conc IgGPA conc IgG2PA Conc RU
4.0496 -1.3341 0.000006 0 0 0
4.9496 -1.3292 0.000006 0 0 0
5.8496 3.6061 0.000006 0 0 0
6.7496 0.5799 5.99E-06 7.20E-09 0.00E+00 0.108000054
7.6496 1.394 5.99E-06 1.44E-08 1.30E-11 0.216060048
8.5496 -0.736 5.98E-06 2.15E-08 3.87E-11 0.324177992
9.4496 4.0143 5.97E-06 2.87E-08 7.72E-11 0.432351916
10.3496 3.7993 5.96E-06 3.58E-08 1.28E-10 0.540579873
11.2496 2.0872 5.96E-06 4.29E-08 1.92E-10 0.648859937
12.1496 0.1757 5.95E-06 4.99E-08 2.67E-10 0.7571902
13.0496 2.9765 5.94E-06 5.70E-08 3.55E-10 0.865568779
Data 1
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complexes also have a response factor (“R factor”), which is the amount of response they 
generate when compared with the ligand. The response factor is set to three for the single-
binding complexes because IgG is roughly three times the size of Protein A. The dual-
binding complexes have a response of six because of the second IgG. The reactions are also 
set on this page, by setting the reacting molecules and reaction constants. The reaction 
constants must be given an initial value, however, if the fit box is selected they will be 
optimised when the model is executed. Figure A.4 shows the data tab where the initial 
concentration of the ligand is set (the value entered is in terms of RU). Again, by selecting 
the fit box the parameter will be optimised during the modelling. The injection concentrations 
and times are also set in this tab by selecting one of the needle buttons on the left hand side. 
Once the model is set up the execution is fast and rapidly optimises all the desired 
parameters. The models can be used on multiple data sets allowing a single model to be used 
for any number of experimental runs. The simplicity of setting up the model, the ability to use 
a single model across multiple runs and the ease of optimisation make ClampXP the most 
efficient program for modelling large numbers of experimental data sets.     
 
Figure A.3: A screen shot of the Model tab in ClampXP. 
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Figure A.4: A screen shot of the Data tab in ClampXP. 
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Appendix B: Full Models Used in Results 
This appendix shows the complete result sets used in the results section. Each individual run 
will be set out with the highest concentration of IgG in the dilution series, buffer makeup, pH 
of the reaction and residual sum of squared errors for the data and model, followed by the 
graph showing the model (red) and data (black). A table of the constants from the reaction 
and the associated errors will also be shown. The results used for the kinetic experiments will 
be presented in the first section with the second section containing the results from the IgG in 
PBST runs. For the IgG in PBST runs all binding took place in PBST at pH 7.4 as noted 
before with the buffer conditions and pH representing only the elution part of the reaction. 
Each run will be denoted using a run and channel number, the run number is largely 
meaningless as it comes from the number of steps used on a particular chip (causing the 
numbers to reset when the chip was changed), while the channel does provide a basis for 
comparison as different channels had different concentrations of Protein A immobilised on 
them.  
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B.1: Data from the Kinetic Experiments 
Run 24, channel 2: Performed at pH 7.4 in PBST, at an IgG concentration of 0.0667 µm. 
Residual sum of squared errors (RSSE) is 2.522. 
 
Figure B.1: Run 24 channel 2 model and data graph. 
Table B.1: Run 24 channel 2 model parameters. 
 
 
 
 
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 57490 4.73E-03 88171 2.52E-05 31632 1.69E-03 73.47
Error (abs) 543.5 5.82E-05 216.2 2.97E-07 356.2 2.69E-05 0.1501
Error (%) 0.95 1.23 0.25 1.18 1.13 1.60 0.20
88 
 
Run 24, channel 3: Performed at pH 7.4 in PBST, at an IgG concentration of 0.0667 µm. 
RSSE is 2.215. 
 
 
Figure B.2: Run 24 channel 3 model and data graph. 
Table B.2: Run 24 channel 3 model parameters. 
 
 
 
 
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 16401 0.00E+00 14999 2.69E-04 39710000 1.18E+01 29.83
Error (abs) 8224 5.16E-05 8157 1.02E-04 39650000 1.18E+01 0.04947
Error (%) 50.14 54.38 37.94 99.85 99.83 0.17
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Run 39, channel 2: Performed at pH 7.4 in PBST, at an IgG concentration of 0.133 µm. 
RSSE is 12.74. 
 
Figure B.3: Run 39 channel 2 model and data graph. 
Table B.3: Run 39 channel 2 model parameters. 
  
 
 
 
 
 
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 27038 5.00E-03 33953 5.42E-05 1.48E+08 7.12E+01 120.6
Error (abs) 821 1.33E-04 146 5.65E-07 3.14E+09 1.51E+03 0.1408
Error (%) 3.04 2.66 0.43 1.04 2125.76 2126.40 0.12
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Run 39, channel 3: Performed at pH 7.4 in PBST, at an IgG concentration of 0.133 µm. 
RSSE is 3.551. 
 
Figure B.4: Run 39 channel 3 model and data graph. 
Table B.4: Run 39 channel 3 model parameters. 
 
 
 
 
 
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 11813 0.00238 26069 6.77E-05 1.65E+08 58.25 27.07
Error (abs) 339.1 0.000103 139.3 1.35E-06 2.89E+09 1023 0.04373
Error (%) 2.870566 4.315126 0.534351 2.000887 1756.527 1756.223 0.1615441
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Run 46, channel 3: Performed at pH 7.4 in PBST, at an IgG concentration of 0.133 µm. 
RSSE is 2.293. 
 
Figure B.5: Run 46 channel 3 model and data graph. 
Table B.5: Run 46 channel 3 model parameters. 
 
 
 
 
 
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 20613 0.00236 49198 7.86E-05 61160000 27.72 20.83
Error (abs) 329.2 8.544E-05 363 1.96E-06 3.44E+08 155.7 0.07252
Error (%) 1.59705 3.620339 0.737835 2.493001 561.9686 561.6883 0.348151704
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Run 53, channel 3: Performed at pH 7.4 in PBST, at an IgG concentration of 0.267 µm. 
RSSE is 4.228. 
 
Figure B.6: Run 53, channel 3 model and data graph. 
Table B.6: Run 46, channel 3 model parameters. 
 
 
 
 
 
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 14154 0.004101 16689 6.05E-05 1.36E+08 64.9 33.88
Error (abs) 446 0.0001222 62.57 8.14E-07 1.57E+09 745.9 0.04519
Error (%) 3.151053 2.979761 0.374918 1.344953 1149.56 1149.307 0.133382527
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Run 60, channel 3: Performed at pH 7.4 in PBST, at an IgG concentration of 0.267 µm. 
RSSE is 2.845. 
 
Figure B.7: Run 60, channel 3 model and data graph. 
Table B.7: Run 60, channel 3 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 16766 0.0005403 23061 0 1.33E+08 50.97 28.03
Error (abs) 2448 0.0000697 2514 1.93E-05 1.91E+08 73.38 0.07415
Error (%) 14.60098 12.900241 10.90152 143.9759 143.967 0.264537995
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Run 67, channel 3: Performed at pH 7.4 in PBST, at an IgG concentration of 0.267 µm. 
RSSE is 2.512. 
 
Figure B.8: Run 67, channel 3 model and data graph. 
Table B.8: Run 67, channel 3 model parameters. 
 
 
 
 
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 9706 0.001973 24332 6.33E-05 1.17E+08 50.04 30.27
Error (abs) 102.5 5.144E-05 106.6 1.26E-06 7.39E+08 316.4 0.0393
Error (%) 1.056048 2.6071972 0.438106 1.98137 632.6199 632.2942 0.129831516
95 
 
Run 74, channel 3: Performed at pH 7.4 in PBST, at an IgG concentration of 0.533 µm. 
RSSE is 3.948. 
 
Figure B.9: Run 74, channel 3 model and data graph. 
Table B.9: Run 74, channel 3 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 10838 0.00351 14167 3.59E-05 67420000 46.75 36.15
Error (abs) 171.6 6.952E-05 52.6 8.87E-07 2.34E+08 161.9 0.05076
Error (%) 1.583318 1.9806268 0.371285 2.469359 346.3364 346.3102 0.140414938
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Run 82, channel 3: Performed at pH 7.4 in PBST, at an IgG concentration of 0.8 µm. RSSE is 
4.589. 
 
Figure B.11: Run 82, channel 3 model and data graph. 
Table B.11: Run 82, channel 3 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 10879 0.004013 10407 6.66E-05 70480000 70.39 40.77
Error (abs) 202.8 7.265E-05 30.95 6.34E-07 2.81E+08 280.7 0.03606
Error (%) 1.864142 1.8103663 0.297396 0.951966 398.6947 398.7782 0.088447388
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Run 89, channel 3: Performed at pH 7.4 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 5.527. 
 
Figure B.12: Run 89, channel 3 model and data graph. 
Table B.12: Run 89, channel 3 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 11794 0.006369 6026 8.41E-05 40330000 79.53 45.83
Error (abs) 256.8 0.0001198 19.9 6.5E-07 3.96E+08 781.9 0.04844
Error (%) 2.177378 1.880986 0.330236 0.773365 982.8911 983.151 0.10569496
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Run 96, channel 3: Performed at pH 7.4 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 5.779. 
 
Figure B.13: Run 96, channel 3 model and data graph. 
Table B.13: Run 96, channel 3 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 10137 0.005919 7029 8.53E-05 68090000 83.62 46.58
Error (abs) 277.7 0.0001378 22.91 6.57E-07 8.99E+08 1103 0.05013
Error (%) 2.739469 2.328096 0.325935 0.769898 1320.018 1319.062 0.107621297
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Run 103, channel 3: Performed at pH 7.4 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 4.277. 
 
Figure B.14: Run 103, channel 3 model and data graph. 
Table B.14: Run 103, channel 3 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 7059 0.001773 13576 4.48E-05 3604000 2.634 37.05
Error (abs) 85.21 0.0000515 103.9 2.26E-06 1377000 1.005 0.07634
Error (%) 1.207111 2.9046813 0.765321 5.050279 38.20755 38.1549 0.206045884
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Run 110, channel 3: Performed at pH 7.4 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 4.656. 
 
Figure B.15: Run 110, channel 3 model and data graph. 
Table B.15: Run 110, channel 3 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 9182 0.004552 6989 8.08E-05 776600 1.032 44.99
Error (abs) 167.5 7.642E-05 20.02 6.06E-07 281400 0.3689 0.03892
Error (%) 1.824221 1.6788225 0.28645 0.749752 36.23487 35.74612 0.086508113
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Run 313, channel 2: Performed at pH 7.4 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 7.731.  
 
Figure B.16: Run 313, channel 2 model and data graph. 
Table B.16: Run 313, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 4180 0.002216 5028 9.21E-05 32905 0.03501 81.64
Error (abs) 65.62 5.22E-05 29.08 1.05E-06 1235 0.001465 0.1078
Error (%) 1.569856 2.356498 0.578361 1.135253 3.753229 4.184519 0.132043116
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Run 320, channel 2: Performed at pH 7.4 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 3.766. 
 
Figure B.17: Run 320, channel 2 model and data graph. 
Table B.17: Run 320, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 6672 0.00233 8883 9.24E-05 11398 0.01769 68.95
Error (abs) 118.6 6.73E-05 100.5 1.08E-06 203.2 0.000743 0.2877
Error (%) 1.777578 2.887983 1.131375 1.163672 1.782769 4.200113 0.417258883
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Run 327, channel 3: Performed at pH 7.4 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 2.731. 
 
Figure B.18: Run 327, channel 3 model and data graph. 
Table B.18: Run 327, channel 3 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 9456 0.004742 9516 0.000136 80.26
Error (abs) 82.67 5.37E-05 97.78 7.75E-07 0.317
Error (%) 0.87426 1.132855 1.027533 0.57 0.394966359
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Run 334, channel 2: Performed at pH 7.4 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 4.242. 
 
Figure B.19: Run 334, channel 2 model and data graph. 
Table B.19: Run 334, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 9456 0.004742 9516 0.000136 80.26
Error (abs) 82.67 5.37E-05 97.78 7.75E-07 0.317
Error (%) 0.87426 1.132855 1.027533 0.57 0.394966359
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Run 341, channel 2: Performed at pH 7.4 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 4.938. 
 
Figure B.20: Run 341, channel 2 model and data graph. 
Table B.20: Run 341, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 4335 0.00217 5197 8.52E-05 28754 0.03835 81.32
Error (abs) 36.31 3E-05 18.52 1.37E-05 805.8 0.001166 0.06834
Error (%) 0.838 1.381 0.356 16.117 2.802 3.040 0.084
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Run 350, channel 2: Performed at pH 7.4 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 2.598. 
 
Figure B.21: Run 350, channel 2 model and data graph. 
Table B.21: Run 350, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 8551 0.001277 12710 1.79E-05 15335 0.009867 55.71
Error (abs) 106 4.98E-05 170.1 9.16E-07 131.4 0.000223 0.1214
Error (%) 1.240 3.896 1.338 5.120 0.857 2.257 0.218
107 
 
Run 358, channel 2: Performed at pH 7.4 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 3.057. 
 
Figure B.22: Run 358, channel 2 model and data graph. 
Table B.22: Run 358, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 4373 0.002168 4860 6.05E-05 21145 0.04696 89.73
Error (abs) 27.25 2.34E-05 24.19 1.07E-06 469.7 0.001093 0.1703
Error (%) 0.623 1.078 0.498 1.767 2.221 2.328 0.190
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Run 365, channel 2: Performed at pH 7.4 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 3.309. 
 
Figure B.23: Run 365, channel 2 model and data graph. 
Table B.23: Run 365, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 3816 0.002638 5235 6.49E-05 19164 0.0451 95.08
Error (abs) 31.7 3.3E-05 23.54 7.6E-07 434.5 0.001114 0.1883
Error (%) 0.831 1.252 0.450 1.173 2.267 2.470 0.198
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Run 372, channel 2: Performed at pH 7.4 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 3.835. 
 
Figure B.24: Run 372, channel 2 model and data graph. 
Table B.24: Run 372, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 4806 0.002565 6412 0.000105 35315 0.06722 84.25
Error (abs) 39.33 3.52E-05 33.56 8.94E-07 1100 0.002134 0.1777
Error (%) 0.818 1.371 0.523 0.850 3.115 3.175 0.211
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Run 387, channel 2: Performed at pH 7.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 3.214. 
 
Figure B.25: Run 387, channel 2 model and data graph. 
Table B.25: Run 387, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 2387 0.002149 2938 9.51E-05 13070 0.0245 68.41
Error (abs) 26.8 3.42E-05 11.23 5.97E-07 279.8 0.000626 0.06673
Error (%) 1.123 1.593 0.382 0.628 2.141 2.555 0.098
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Run 394, channel 2: Performed at pH 7.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 4.073. 
 
Figure B.26: Run 394, channel 2 model and data graph. 
Table B.26: Run 394, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 2394 0.001624 2889 7.8E-05 14220 0.02344 67.09
Error (abs) 22.93 3.5E-05 21.01 1.15E-06 357.7 0.000675 0.08101
Error (%) 0.958 2.156 0.727 1.470 2.515 2.879 0.121
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Run 410, channel 2: Performed at pH 7.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 4.777. 
 
Figure B.27: Run 410, channel 2 model and data graph. 
Table B.27: Run 410, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 6313 0.002376 5799 6.59E-05 1.23E+08 132.8 43.87
Error (abs) 67.66 4.45E-05 35.77 7.46E-07 2.61E+08 282.1 0.0664
Error (%) 1.072 1.871 0.617 1.131 212.296 212.425 0.151
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Run 417, channel 2: Performed at pH 7.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 3.449. 
 
Figure B.28: Run 417, channel 2 model and data graph. 
Table B.28: Run 417, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 5332 0.003284 4709 0.000138 84420000 221.6 51.89
Error (abs) 44.43 3.7E-05 16.39 8.11E-07 2.33E+09 6107 0.07284
Error (%) 0.833 1.127 0.348 0.588 2757.640 2755.866 0.140
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Run 424, channel 2: Performed at pH 7.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 4.466. 
 
Figure B.29: Run 424, channel 2 model and data graph. 
Table B.29: Run 424, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 3436 0.003064 3273 0.000109 90350000 202.9 60.2
Error (abs) 39.76 4.32E-05 13.84 1.11E-06 1.39E+09 3114 0.1002
Error (%) 1.157 1.410 0.423 1.015 1536.248 1534.746 0.166
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Run 431, channel 2: Performed at pH 7.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 4.822. 
 
Figure B.30: Run 431, channel 2 model and data graph. 
Table B.30: Run 431, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 3240 0.00296 3352 0.000111 93500000 197.3 60.08
Error (abs) 37.96 5.27E-05 17.63 5.73E-06 6E+08 1265 0.09547
Error (%) 1.172 1.779 0.526 5.185 641.283 641.156 0.159
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Run 438, channel 2: Performed at pH 7.0 in PBST, at an IgG concentration of 0.5 µm. RSSE 
is 2.663. 
 
Figure B.31: Run 438, channel 2 model and data graph. 
Table B.31: Run 438, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 5490 0.002082 6144 8.85E-05 1574000000 1777 44.56
Error (abs) 33.75 2.66E-05 27.03 0.001548 1.881E+11 212400 0.05449
Error (%) 0.615 1.276 0.440 1749.746 11950.445 11952.729 0.122
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Run 445, channel 2: Performed at pH 7.0 in PBST, at an IgG concentration of 0.5 µm. RSSE 
is 2.741. 
 
Figure B.32: Run 445, channel 2 model and data graph. 
Table B.32: Run 445, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 7495 0.00245 7636 8.05E-05 1392000000 2205 40.96
Error (abs) 49.11 3.3E-05 32.42 0.000371 2.368E+10 37506 0.05074
Error (%) 0.655 1.347 0.425 460.907 1701.149 1700.952 0.124
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Run 462, channel 3: Performed at pH 7.4 in PBST, at an IgG concentration of 5.733 µm. 
RSSE is 3.056. 
 
Figure B.33: Run 462, channel 3 model and data graph. 
Table B.33: Run 462, channel 3 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 7022 0.009264 1377 0.0001418 46.96
Error (abs) 65.38 9.11E-05 4.11 1.403 0.05018
Error (%) 0.931 0.984 0.298 989421.721 0.107
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Run 469, channel 3: Performed at pH 7.4 in PBST, at an IgG concentration of 5.733 µm. 
RSSE is 2.916. 
 
Figure B.34: Run 469, channel 3 model and data graph. 
Table B.34: Run 469, channel 3 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 9247 0.01303 1658 0.0002344 43.95
Error (abs) 110.1 0.000165 6.041 1.403 0.0506
Error (%) 1.191 1.263 0.364 598549.488 0.115
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Run 485, channel 2: Performed at pH 6.5 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 10.91. 
 
Figure B.35: Run 485, channel 2 model and data graph. 
Table B.35: Run 485, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 2755 0.000119 3700 0.003712 8961000 21.67 92.22
Error (abs) 16.75 1.51E-06 72.11 1.403 54990000 133 0.2124
Error (%) 0.608 1.268 1.949 37796.336 613.659 613.752 0.230
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Run 492, channel 3: Performed at pH 6.5 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 1.941. 
 
Figure B.36: Run 492, channel 3 model and data graph. 
Table B.36: Run 492, channel 3 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 4819 0.000104 6677 0.002799 26880000 36.07 17.9
Error (abs) 28.35 1.69E-06 82.5 1.403 346600000 464.9 0.02742
Error (%) 0.588 1.619 1.236 50125.045 1289.435 1288.883 0.153
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Run 499, channel 2: Performed at pH 6.5 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 4.586. 
 
Figure B.37: Run 499, channel 2 model and data graph. 
Table B.37: Run 499, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 3853 0.000116 4908 0.003761 1452000000 2434 78.81
Error (abs) 12.67 6.46E-07 52.89 1.403 7.928E+10 132900 0.1453
Error (%) 0.329 0.557 1.078 37303.909 5460.055 5460.148 0.184
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Run 499, channel 3: Performed at pH 6.5 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 2.444. 
 
Figure B.38: Run 499, channel 3 model and data graph. 
Table B.38: Run 499, channel 3 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 4536 9.88E-05 5129 0.003657 1599000000 2035 16.65
Error (abs) 27.81 1.49E-06 145.1 1.403 4.504E+11 573300 0.06062
Error (%) 0.613 1.508 2.829 38364.780 28167.605 28171.990 0.364
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Run 506, channel 2: Performed at pH 6.5 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 3.735. 
 
Figure B.39: Run 506, channel 2 model and data graph. 
Table B.39: Run 506, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 3466 0.000115 4813 0.003389 214100000 612.6 78.64
Error (abs) 9.007 5.82E-07 30.84 1.403 8454000000 24183 0.09663
Error (%) 0.260 0.508 0.641 41398.643 3948.622 3947.600 0.123
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Run 506, channel 3: Performed at pH 6.5 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 2.589. 
 
Figure B.40: Run 506, channel 3 model and data graph. 
Table B.40: Run 506, channel 3 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 3442 9.99E-05 4194 0.00273 243600000 425.7 16.86
Error (abs) 34.25 2.37E-06 92.91 1.403 2.497E+10 43633 0.08578
Error (%) 0.995 2.372 2.215 51391.941 10250.411 10249.706 0.509
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Run 513, channel 2: Performed at pH 6.5 in PBST, at an IgG concentration of 1.5 µm. RSSE 
is 7.921. 
 
Figure B.41: Run 513, channel 2 model and data graph. 
Table B.41: Run 513, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 1867 0.000122 2530 0.003343 201900000 500 103.2
Error (abs) 9.829 1.15E-06 32.59 1.403 8574000000 21233 0.1606
Error (%) 0.526 0.939 1.288 41968.292 4246.657 4246.600 0.156
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Run 520, channel 2: Performed at pH 6.5 in PBST, at an IgG concentration of 1.5 µm. RSSE 
is 9.985. 
 
Figure B.42: Run 520, channel 2 model and data graph. 
Table B.42: Run 520, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 3477 0.000105 3958 0.002679 273800000 418.4 75.87
Error (abs) 22.66 1.79E-06 56.46 1.403 5910000000 9030 0.1298
Error (%) 0.652 1.705 1.426 52370.287 2158.510 2158.222 0.171
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Run 527, channel 2: Performed at pH 6.5 in PBST, at an IgG concentration of 0.5 µm. RSSE 
is 5.65. 
 
Figure B.43: Run 527, channel 2 model and data graph. 
Table B.43: Run 527, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 3038 0.000141 3763 0.003885 100100000 202.9 80.81
Error (abs) 16.64 1.23E-06 68.73 1.403 396100000 802.8 0.2159
Error (%) 0.548 0.873 1.826 36113.256 395.704 395.663 0.267
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Run 536, channel 2: Performed at pH 6.5 in PBST, at an IgG concentration of 0.5 µm. RSSE 
is 6.389. 
 
Figure B.44: Run 536, channel 2 model and data graph. 
Table B.44: Run 536, channel 2 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 2828 0.000178 4208 0.004911 107700000 286.5 81.99
Error (abs) 19.57 1.37E-06 113.4 1.403 4180000000 11119 0.3085
Error (%) 0.692 0.771 2.695 28568.520 3881.151 3880.977 0.376
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Run 552, channel 3: Performed at pH 6.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 2.402. 
 
Figure B.45: Run 552, channel 3 model and data graph. 
Table B.45: Run 552, channel 3 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 2445 0.000458 5057 0.009021 105200000 596.4 25.54
Error (abs) 26.76 5.98E-06 179.5 1.403 7818000000 44261 0.1182
Error (%) 1.094 1.305 3.550 15552.599 7431.559 7421.362 0.463
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Run 566, channel 3: Performed at pH 6.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 2.064. 
 
Figure B.46: Run 566, channel 3 model and data graph. 
Table B.46: Run 566, channel 3 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 3577 0.000155 4356 0.003034 130300000 186.7 18.7
Error (abs) 22.23 1.69E-06 67.82 1.403 3471000000 4972 0.03498
Error (%) 0.621 1.092 1.557 46242.584 2663.853 2663.096 0.187
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Run 566, channel 5: Performed at pH 6.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 9.70. 
 
Figure B.47: Run 566, channel 5 model and data graph. 
Table B.47: Run 566, channel 5 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 8209 0.0001 8528 0.003672 202700000 166.5 96.48
Error (abs) 36.48 8.21E-07 142.2 1.403 1897000000 1558 0.09867
Error (%) 0.444 0.820 1.667 38208.061 935.866 935.736 0.102
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Run 573, channel 5: Performed at pH 6.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 9.056. 
 
Figure B.48: Run 573, channel 5 model and data graph. 
Table B.48: Run 573, channel 5 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 9545 0.000109 9359 0.003171 131700000 97.85 88.78
Error (abs) 35.01 9.15E-07 121.9 1.403 1161000000 862.7 0.08539
Error (%) 0.367 0.837 1.302 44244.718 881.549 881.656 0.096
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Run 581, channel 2: Performed at pH 6.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 8.364. 
 
Figure B.49: Run 581, channel 2 model and data graph. 
Table B.49: Run 581, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 4047 0.000155 7455 0.005712 1193000000 2253 90.02
Error (abs) 16.75 8.96E-07 139.2 1.403 9.209E+10 173900 0.1512
Error (%) 0.414 0.578 1.867 24562.325 7719.195 7718.597 0.168
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Run 581, channel 3: Performed at pH 6.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 3.668. 
 
Figure B.50: Run 581, channel 3 model and data graph. 
Table B.50: Run 581, channel 3 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 3149 0.000347 8654 0.01506 1045000000 2664 23.01
Error (abs) 42.46 8.48E-06 790.8 1.403 1.564E+12 3987000 0.1192
Error (%) 1.348 2.445 9.138 9316.069 149665.072 149662.162 0.518
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Run 597, channel 5: Performed at pH 6.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 8.55. 
 
Figure B.51: Run 597, channel 5 model and data graph. 
Table B.51: Run 597, channel 5 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 17379 4.88E-05 12451 0.0027 1208000000 482.1 71.54
Error (abs) 104.5 1.09E-06 234.8 1.403 1.165E+11 46507 0.09143
Error (%) 0.601 2.224 1.886 51962.963 9644.040 9646.754 0.128
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Run 604, channel 2: Performed at pH 6.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 5.641. 
 
Figure B.52: Run 604, channel 2 model and data graph. 
Table B.52: Run 604, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 4271 0.000122 5028 0.002961 589700000 820.3 83.22
Error (abs) 17.13 9.41E-07 43.79 1.403 2.577E+10 35840 0.1104
Error (%) 0.401 0.772 0.871 47382.641 4370.019 4369.133 0.133
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Run 604, channel 3: Performed at pH 6.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 2.48. 
 
Figure B.53: Run 604, channel 3 model and data graph. 
Table B.53: Run 604, channel 3 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 7927 7.52E-05 6818 0.003422 817600000 770.1 14.1
Error (abs) 90.23 1.82E-06 232.9 1.403 1.744E+11 164200 0.04588
Error (%) 1.138 2.425 3.416 40999.416 21330.724 21321.906 0.325
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Run 611, channel 3: Performed at pH 6.0 in PBST, at an IgG concentration of 1.5 µm. RSSE 
is 2.364. 
 
Figure B.54: Run 611, channel 3 model and data graph. 
Table B.54: Run 611, channel 3 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 1481 0.000458 6832 0.01467 29.45
Error (abs) 11.57 3.72E-06 142.8 1.403 0.09733
Error (%) 0.781 0.812 2.090 9563.736 0.330
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Run 611, channel 5: Performed at pH 6.0 in PBST, at an IgG concentration of 1.5 µm. RSSE 
is 9.692. 
 
Figure B.55: Run 611, channel 5 model and data graph. 
Table B.55: Run 611, channel 5 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 5612 9.68E-05 15998 0.007418 96.18
Error (abs) 18.81 6.06E-07 187.5 1.403 0.09853
Error (%) 0.335 0.626 1.172 18913.454 0.102
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Run 633, channel 2: Performed at pH 6.0 in PBST, at an IgG concentration of 0.5 µm. RSSE 
is 5.076. 
 
Figure B.56: Run 633, channel 2 model and data graph. 
Table B.56: Run 633, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 4439 0.000155 10734 0.006111 83.08
Error (abs) 17.02 7.29E-07 102.8 1.403 0.1398
Error (%) 0.383 0.469 0.958 22958.599 0.168
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Run 640, channel 2: Performed at pH 6.0 in PBST, at an IgG concentration of 0.5 µm. RSSE 
is 6.002. 
 
Figure B.57: Run 640, channel 2 model and data graph. 
Table B.57: Run 640, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 5318 0.000132 12785 0.005704 75.08
Error (abs) 23.48 8.64E-07 139.8 1.403 0.1345
Error (%) 0.442 0.655 1.093 24596.774 0.179
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Run 7, channel 5: Performed at pH 6.0 in Sodium Acetate, at an IgG concentration of 1.067 
µm. RSSE is 6.577. 
 
Figure B.58: Run 7, channel 5 model and data graph. 
Table B.58: Run 7, channel 5 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 6114 0.001705 8133 5.99E-05 50407 0.02506 87
Error (abs) 63.77 3.507E-05 44.67 1.51E-06 1000 0.000582 0.06757
Error (%) 1.043 2.057 0.549 2.516 1.984 2.322 0.078
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Run 16, channel 2: Performed at pH 6.0 in Sodium Acetate, at an IgG concentration of 1.067 
µm. RSSE is 7.487. 
 
Figure B.59: Run 16, channel 2 model and data graph. 
Table B.59: Run 16, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 6172 0.002596 5540 8.01E-05 73823 0.08835 73.35
Error (abs) 72.91 4.317E-05 26.93 1.32E-06 4452 0.005486 0.09246
Error (%) 1.181 1.663 0.486 1.648 6.031 6.209 0.126
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Run 16, channel 3: Performed at pH 6.0 in Sodium Acetate, at an IgG concentration of 1.067 
µm. RSSE is 1.917. 
 
Figure B.60: Run 16, channel 3 model and data graph. 
Table B.60: Run 16, channel 3 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 4004 0.001911 3459 8.18E-05 23315 0.04064 15.52
Error (abs) 51.27 4.782E-05 34.64 2.87E-06 1533 0.00281 0.03086
Error (%) 1.280 2.502 1.001 3.509 6.575 6.914 0.199
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Run 38, channel 2: Performed at pH 6.0 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 4.995. 
 
Figure B.61: Run 38, channel 2 model and data graph. 
Table B.61: Run 38, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 5313 0.002493 4815 8.88E-05 37727 0.04947 71.93
Error (abs) 49.14 3.213E-05 18.31 1.06E-06 1305 0.001829 0.07035
Error (%) 0.925 1.289 0.380 1.191 3.459 3.697 0.098
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Run 38, channel 3: Performed at pH 6.0 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 2.004. 
 
Figure B.62: Run 38, channel 3 model and data graph. 
Table B.62: Run 38, channel 3 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 3011 0.00185 2552 3.84E-05 13609 0.01941 15.7
Error (abs) 74.11 6.878E-05 33.21 3.59E-06 616 0.001102 0.03879
Error (%) 2.461 3.718 1.301 9.331 4.526 5.677 0.247
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Run 43, channel 2: Performed at pH 6.0 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 2.962. 
 
Figure B.63: Run 43, channel 2 model and data graph. 
Table B.63: Run 43, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 3032 0.001805 3256 9.07E-05 17174 0.02331 83.76
Error (abs) 17.79 1.964E-05 11.84 1.01E-06 224.3 0.000359 0.05358
Error (%) 0.587 1.088 0.364 1.117 1.306 1.541 0.064
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Run 43, channel 3: Performed at pH 6.0 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 1.916. 
 
Figure B.64: Run 43, channel 3 model and data graph. 
Table B.64: Run 43, channel 3 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 4750 0.0007959 1404 0 18471 0.01984 15
Error (abs) 137.6 3.747E-05 170.5 2.54E-05 709.6 0.00084 0.0352
Error (%) 2.897 4.708 12.144 3.842 4.233 0.235
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Run 48, channel 2: Performed at pH 6.0 in sodium acetate, at an IgG concentration of 1.5 µm. 
RSSE is 8.123. 
 
Figure B.65: Run 48, channel 2 model and data graph. 
Table B.65: Run 48, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 4217 0.002677 3513 0.000101 35956 0.05294 80.46
Error (abs) 61.49 4.916E-05 19.43 1.54E-06 1716 0.0027 0.1149
Error (%) 1.458 1.836 0.553 1.521 4.772 5.100 0.143
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Run 59, channel 2: Performed at pH 6.0 in sodium acetate, at an IgG concentration of 0.5 µm. 
RSSE is 4.38. 
 
Figure B.66: Run 59, channel 2 model and data graph. 
Table B.66: Run 59, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 10208 0.002524 8941 8.51E-05 21348 0.04545 51.19
Error (abs) 100.9 0.0000389 41.77 1.25E-06 2190 0.004621 0.07234
Error (%) 0.988 1.541 0.467 1.472 10.259 10.167 0.141
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Run 64, channel 2: Performed at pH 6.0 in sodium acetate, at an IgG concentration of 0.5 µm. 
RSSE is 4.476. 
 
Figure B.67: Run 64, channel 2 model and data graph. 
Table B.67: Run 64, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 6784 0.002606 6020 0.000108 46668 0.0356 61.98
Error (abs) 105.5 4.833E-05 31.75 1.45E-06 1580 0.001374 0.09543
Error (%) 1.555 1.855 0.527 1.344 3.386 3.860 0.154
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Run 75, channel 5: Performed at pH 5.5 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 9.746. 
 
Figure B.68: Run 75, channel 5 model and data graph. 
Table B.68: Run 75, channel 5 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 5668 0.001527 9045 6.94E-05 54179 0.0221 88.85
Error (abs) 89.99 5.882E-05 90.81 2.7E-06 1361 0.000661 0.0994
Error (%) 1.588 3.852 1.004 3.884 2.512 2.990 0.112
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Run 80, channel 2: Performed at pH 5.5 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 10.69. 
 
Figure B.69: Run 80, channel 2 model and data graph. 
Table B.69: Run 80, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 2100 0.001994 2336 8.21E-05 23780 0.03395 109
Error (abs) 42.22 6.661E-05 23.12 2.75E-06 999.5 0.001574 0.2494
Error (%) 2.010 3.341 0.990 3.354 4.203 4.636 0.229
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Run 85, channel 2: Performed at pH 5.5 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 7.782. 
 
Figure B.70: Run 85, channel 2 model and data graph. 
Table B.70: Run 85, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 2854 0.002459 2768 6.07E-05 23694 0.0326 96.85
Error (abs) 54.83 5.582E-05 16.12 1.54E-06 769.7 0.00123 0.1626
Error (%) 1.921 2.270 0.582 2.539 3.249 3.773 0.168
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Run 96, channel 2: Performed at pH 5.5 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 6.284. 
 
Figure B.71: Run 96, channel 2 model and data graph. 
Table B.71: Run 96, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 2652 0.002143 2927 7.49E-05 24556 0.0327 104.1
Error (abs) 32.44 3.856E-05 14.16 1.34E-06 595.9 0.000896 0.1237
Error (%) 1.223 1.799 0.484 1.791 2.427 2.739 0.119
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Run 96, channel 3: Performed at pH 5.5 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 2.808. 
 
Figure B.72: Run 96, channel 3 model and data graph. 
Table B.72: Run 96, channel 3 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 2469 0.002142 2829 7.09E-05 15219 0.0204 14.46
Error (abs) 140.5 0.0001531 46.66 4.52E-06 1009 0.001751 0.05666
Error (%) 5.691 7.148 1.649 6.380 6.630 8.583 0.392
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Run 107, channel 5: Performed at pH 5.5 in sodium acetate, at an IgG concentration of 1.5 
µm. RSSE is 5.697. 
 
Figure B.73: Run 107, channel 5 model and data graph. 
Table B.73: Run 107, channel 5 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 2332 0.001332 3449 4.67E-05 20634 0.02081 90.26
Error (abs) 21.86 3.579E-05 29.99 2.23E-06 345.6 0.000406 0.07953
Error (%) 0.937 2.687 0.870 4.773 1.675 1.952 0.088
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Run 117, channel 2: Performed at pH 5.5 in sodium acetate, at an IgG concentration of 0.5 
µm. RSSE is 4.442. 
 
Figure B.74: Run 117, channel 2 model and data graph. 
Table B.74: Run 117, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 7441 0.00203 11421 3.66E-05 270200 0.109 47.5
Error (abs) 105.5 5.043E-05 58.8 1.42E-06 14231 0.006018 0.05859
Error (%) 1.418 2.484 0.515 3.878 5.267 5.521 0.123
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Run 128, channel 2: Performed at pH 5.5 in sodium acetate, at an IgG concentration of 1.5 
µm. RSSE is 6.90. 
 
Figure B.75: Run 128, channel 2 model and data graph. 
Table B.75: Run 128, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 1103 0.001927 1090 0.000108 12139 0.02793 133.6
Error (abs) 14.2 0.0000427 8.595 2.2E-06 241.4 0.000648 0.2328
Error (%) 1.287 2.216 0.789 2.031 1.989 2.321 0.174
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Run 134, channel 2: Performed at pH 5.5 in sodium acetate, at an IgG concentration of 0.5 
µm. RSSE is 3.462. 
 
Figure B.76: Run 134, channel 2 model and data graph. 
Table B.76: Run 134, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 2365 0.001627 3063 6.28E-05 18731 0.02224 70.22
Error (abs) 29.88 4.418E-05 25.65 2.21E-06 447.3 0.000625 0.1327
Error (%) 1.263 2.715 0.837 3.517 2.388 2.810 0.189
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Run 143, channel 2: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 7.557. 
 
Figure B.77: Run 143, channel 2 model and data graph. 
Table B.77: Run 143, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 1590 0.00192 2510 4.93E-05 14211 0.02616 161.6
Error (abs) 19.59 3.893E-05 10.48 1.11E-06 294.8 0.000625 0.1774
Error (%) 1.232 2.028 0.418 2.254 2.074 2.390 0.110
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Run 148, channel 2: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 13.95. 
 
Figure B.78: Run 148, channel 2 model and data graph. 
Table B.78: Run 148, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 161.1 0.002568 321.2 0.00009 1889 0.02134 544.1
Error (abs) 11.18 0.0001747 5.045 1.99E-06 69.16 0.001043 6.582
Error (%) 6.940 6.803 1.571 2.214 3.661 4.888 1.210
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Run 153, channel 5: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 20.77. 
 
Figure B.79: Run 153, channel 5 model and data graph. 
Table B.79: Run 153, channel 5 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 1366 0.0001516 1393 0 10403 0.01425 191.2
Error (abs) 9330 0.0006219 9350 0.000434 295.4 0.000464 0.4909
Error (%) 683.016 410.224 671.213 2.840 3.259 0.257
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Run 158, channel 2: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 7.403. 
 
Figure B.80: Run 158, channel 2 model and data graph. 
Table B.80: Run 158, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 1725 0.001747 3671 4.53E-05 83825 0.1006 132.4
Error (abs) 19.58 4.661E-05 17.88 1.37E-06 3446 0.004207 0.1358
Error (%) 1.135 2.668 0.487 3.020 4.111 4.182 0.103
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Run 171, channel 2: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 1.5 
µm. RSSE is 6.622. 
 
Figure B.81: Run 171, channel 2 model and data graph. 
Table B.81: Run 171, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 294.1 0.001421 605.5 3.78E-05 5556 0.02649 225.6
Error (abs) 3.649 4.868E-05 4.833 1.98E-06 91.72 0.000499 0.494
Error (%) 1.241 3.426 0.798 5.241 1.651 1.882 0.219
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Run 176, channel 2: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 0.5 
µm. RSSE is 6.466. 
 
Figure B.82: Run 176, channel 2 model and data graph. 
Table B.82: Run 176, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 5629 0.002585 6437 7.63E-05 70902 0.07616 59.46
Error (abs) 104.6 0.0000681 42.01 1.71E-06 5937 0.006559 0.1321
Error (%) 1.858 2.634 0.653 2.241 8.374 8.612 0.222
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Run 176, channel 3: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 0.5 
µm. RSSE is 1.781. 
 
Figure B.83: Run 176, channel 3 model and data graph. 
Table B.83: Run 176, channel 3 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 6301 0.005535 4147 0.000326 41682 0.06999 12.74
Error (abs) 522.4 0.0006209 163.5 3.13E-05 6302 0.01288 0.08052
Error (%) 8.291 11.218 3.943 9.586 15.119 18.403 0.632
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Run 181, channel 2: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 0.5 
µm. RSSE is 6.028. 
 
Figure B.84: Run 181, channel 2 model and data graph. 
Table B.84: Run 181, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 2483 0.0001124 7044 0.008284 84.63
Error (abs) 18.8 1.017E-06 125.9 0.000164 0.3791
Error (%) 0.757 0.905 1.787 1.976 0.448
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Run 181, channel 5: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 0.5 
µm. RSSE is 9.984. 
 
Figure B.85: Run 181, channel 5 model and data graph. 
Table B.85: Run 181, channel 5 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 11428 4.899E-05 5245 0.001639 106600 0.0428 72.32
Error (abs) 116.7 2.799E-06 119.6 9.07E-05 5360 0.002294 0.1291
Error (%) 1.021 5.713 2.280 5.536 5.028 5.360 0.179
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Run 187, channel 2: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 3.70. 
 
Figure B.86: Run 187, channel 2 model and data graph. 
Table B.86: Run 187, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 3395 9.795E-05 4708 0.002282 16106 0.01672 45.91
Error (abs) 22.38 1.833E-06 92.25 4.67E-05 360.2 0.000539 0.05488
Error (%) 0.659 1.871 1.959 2.047 2.236 3.226 0.120
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Run 187, channel 5: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 9.193. 
 
Figure B.87: Run 187, channel 5 model and data graph. 
Table B.87: Run 187, channel 5 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 1553 0.0000842 4602 0.007504 90.93
Error (abs) 6.574 7.582E-07 59.36 0.000103 0.1425
Error (%) 0.423 0.900 1.290 1.377 0.157
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Run 192, channel 2: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 3.0 
µm. RSSE is 10.54. 
 
Figure B.88: Run 192, channel 2 model and data graph. 
Table B.88: Run 192, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 2305 0.0001025 11447 0.01303 85.48
Error (abs) 10.1 7.682E-07 201.4 0.00023 0.1337
Error (%) 0.438 0.749 1.759 1.764 0.156
174 
 
Run 198, channel 2: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 0.5 
µm. RSSE is 4.977. 
 
Figure B.89: Run 198, channel 2 model and data graph. 
Table B.89: Run 198, channel 2 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 826.5 0.0001301 1798 0.006192 161.5
Error (abs) 13 1.15E-06 33.87 0.000112 2.063
Error (%) 1.573 0.884 1.884 1.814 1.277
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B.2: Data from IgG in PBST Experiments 
Run 189, channel 4: Performed at pH 4.5 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 2.723. 
 
Figure B.90: Run 189, channel 4 model and data graph. 
Table B.90: Run 189, channel 4 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 46210 0.0763 1630 0.000108 10538 0.006885 37.22
Error (abs) 2339 0.004519 9.192 1.47E-06 211.7 9.06E-05 0.07445
Error (%) 5.062 5.923 0.564 1.370 2.009 1.315 0.200
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Run 220, channel 3: Performed at pH 4.5 in sodium acetate, at an IgG concentration of 3.0 
µm. RSSE is 2.92. 
 
Figure B.91: Run 220, channel 3 model and data graph. 
Table B.91: Run 220, channel 3 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 48197 0.1 959.6 2.52E-05 2840 0.006171 26.79
Error (abs) 2333 0.00553 5.682 1.34E-06 107.6 0.000159 0.05545
Error (%) 4.841 5.530 0.592 5.316 3.789 2.573 0.207
177 
 
Run 220, channel 4: Performed at pH 4.5 in sodium acetate, at an IgG concentration of 3.0 
µm. RSSE is 5.088. 
 
Figure B.92: Run 220, channel 4 model and data graph. 
Table B.92: Run 220, channel 4 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 70223 0.1479 929.7 4.47E-05 5518 0.008435 51.58
Error (abs) 4147 0.009674 5.258 1.32E-06 159.1 0.000159 0.09631
Error (%) 5.905 6.541 0.566 2.948 2.883 1.883 0.187
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Run 237, channel 4: Performed at pH 4.0 in sodium acetate, at an IgG concentration of 0.5 
µm. RSSE is 3.922. 
 
Figure B.93: Run 237, channel 4 model and data graph. 
Table B.93: Run 237, channel 4 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 5164 0.000245 48901 0.00931 3014000 0.5878 17.24
Error (abs) 97.88 6.793E-06 2731 0.000364 633500 0.1262 0.07389
Error (%) 1.895 2.773 5.585 3.913 21.019 21.470 0.429
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Run 248, channel 4: Performed at pH 4.0 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 3.402. 
 
Figure B.94: Run 248, channel 4 model and data graph. 
Table B.94: Run 248, channel 4 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 720.2 0.0001143 5660 0.008892 110900 0.198 42.92
Error (abs) 6.995 2.469E-06 189.5 0.000197 7951 0.01533 0.1831
Error (%) 0.971 2.160 3.348 2.215 7.170 7.742 0.427
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Run 258, channel 4: Performed at pH 4.0 in sodium acetate, at an IgG concentration of 3.0 
µm. RSSE is 3.582. 
 
Figure B.95: Run 258, channel 4 model and data graph. 
Table B.95: Run 258, channel 4 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 244.5 9.554E-05 1898 0.01025 74083 0.3248 70.69
Error (abs) 1.512 1.505E-06 48.77 0.000175 3483 0.01621 0.1965
Error (%) 0.618 1.575 2.570 1.704 4.701 4.991 0.278
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Run 263, channel 4: Performed at pH 4.0 in sodium acetate, at an IgG concentration of 3.0 
µm. RSSE is 4.363. 
 
Figure B.96: Run 263, channel 4 model and data graph. 
Table B.96: Run 263, channel 4 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 638.7 3.283E-05 4643 0.009398 119500 0.2519 45.85
Error (abs) 4.102 1.548E-06 143 0.000191 7938 0.01787 0.09948
Error (%) 0.642 4.715 3.080 2.032 6.643 7.094 0.217
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Run 280, channel 4: Performed at pH 3.5 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 7.355. 
 
Figure B.97: Run 280, channel 4 model and data graph. 
Table B.97: Run 280, channel 4 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 961.2 0.001209 11913 0.01187 7896000 2.974 25.66
Error (abs) 131.7 0.0001245 1793 0.001508 2801000 1.064 0.1805
Error (%) 13.702 10.298 15.051 12.704 35.474 35.777 0.703
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Run 290, channel 4: Performed at pH 3.5 in sodium acetate, at an IgG concentration of 3.0 
µm. RSSE is 10.65. 
 
Figure B.98: Run 290, channel 4 model and data graph. 
Table B.98: Run 290, channel 4 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 149.8 0.0002294 2782 0.01243 4255000 6.241 56.65
Error (abs) 5.876 1.754E-05 316.9 0.000985 3920000 5.754 0.3469
Error (%) 3.923 7.646 11.391 7.924 92.127 92.197 0.612
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Run 350, channel 4: Performed at pH 3.0 in sodium acetate, at an IgG concentration of 3.0 
µm. RSSE is 7.049. 
 
Figure B.99: Run 350, channel 4 model and data graph. 
Table B.99: Run 350, channel 4 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 241.1 0.0002495 30610 0.07583 2.14E+08 210.4 79.65
Error (abs) 3.212 6.362E-06 3014 0.004758 8.23E+08 810.6 0.1613
Error (%) 1.332 2.550 9.846 6.275 384.759 385.266 0.203
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Run 362, channel 4: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 3.296. 
 
Figure B.100: Run 362, channel 4 model and data graph. 
Table B.100: Run 362, channel 4 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 1056 4.942E-05 11593 0.01639 42.89 -8.858 571.5
Error (abs) 8.941 1.123E-06 196.2 0.000285 0.1991 0.4923 0.8206
Error (%) 0.847 2.272 1.692 1.736 0.464 -5.558 0.144
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Run 372, channel 4: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 2.453. 
 
Figure B.101: Run 372, channel 4 model and data graph. 
Table B.101: Run 372, channel 4 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 3671 0.0001645 21283 0.01195 26.59 16.05 561.5
Error (abs) 37.05 7.941E-06 321.2 0.000223 0.06972 0.3361 0.902
Error (%) 1.009 4.827 1.509 1.862 0.262 2.094 0.161
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Run 400, channel 4: Performed at pH 7.4 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 2.806. 
 
Figure B.102: Run 400, channel 4 model and data graph. 
Table B.102: Run 400, channel 4 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 3268 0.0003312 156600 0.7298 7226 0.01363 21.02
Error (abs) 38.47 8.827E-06 81998 0.3873 511.9 0.000843 0.0845
Error (%) 1.177 2.665 52.361 53.069 7.084 6.185 0.402
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Run 410, channel 4: Performed at pH 7.4 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 1.901. 
 
Figure B.103: Run 410, channel 4 model and data graph. 
Table B.103: Run 410, channel 4 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 6919 0.0001738 4134 0.003267 42013 0.1195 14.93
Error (abs) 263.5 2.587E-05 158.9 0.000386 6458 0.01904 0.03019
Error (%) 3.808 14.885 3.844 11.827 15.371 15.933 0.202
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Run 421, channel 4: Performed at pH 7.4 in PBST, at an IgG concentration of 3.0 µm. RSSE 
is 1.093. 
 
Figure B.104: Run 421, channel 4 model and data graph. 
Table B.104: Run 421, channel 4 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 1682 0.001204 1960 5.82E-06 9273 0.01488 20.28
Error (abs) 34.39 0.0000695 49.57 5.82E-06 316.4 0.000653 0.1274
Error (%) 2.045 5.772 2.529 100.052 3.412 4.389 0.628
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Run 426, channel 3: Performed at pH 7.4 in PBST, at an IgG concentration of 3.0 µm. RSSE 
is 1.784. 
 
Figure B.105: Run 426, channel 3 model and data graph. 
Table B.105: Run 426, channel 3 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 1157 0.0004721 6295 0.02064 13.45 -8.344 583.5
Error (abs) 13.8 8.485E-06 226.5 0.000806 0.05704 0.5861 1.365
Error (%) 1.193 1.797 3.598 3.904 0.424 -7.024 0.234
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Run 426, channel 4: Performed at pH 7.4 in PBST, at an IgG concentration of 3.0 µm. RSSE 
is 2.896. 
 
Figure B.106: Run 426, channel 4 model and data graph. 
Table B.106: Run 426, channel 4 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 2993 0.003293 2509 0.000122 20966 0.07029 22.59
Error (abs) 150.9 0.0004878 260.8 7.67E-05 1632 0.006531 0.0417
Error (%) 5.042 14.813 10.395 62.920 7.784 9.292 0.185
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Run 434, channel 4: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 1.688. 
 
Figure B.107: Run 434, channel 4 model and data graph. 
Table B.107: Run 434, channel 4 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 891.4 0.0002104 4604 0.01284 3350000 46 29.38
Error (abs) 13.38 7.809E-06 279.1 0.000402 73730000 1007 0.2797
Error (%) 1.501 3.712 6.062 3.130 2200.896 2189.130 0.952
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Run 439, channel 5: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 2.804. 
 
Figure B.108: Run 439, channel 5 model and data graph. 
Table B.108: Run 439, channel 5 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 4878 0.0002813 34457 0.01565 14180000 18.55 30.95
Error (abs) 25.2 2.293E-06 732.5 0.00026 13210000 17.26 0.04883
Error (%) 0.517 0.815 2.126 1.660 93.159 93.046 0.158
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Run 444, channel 5: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 3.81. 
 
Figure B.109: Run 444, channel 5 model and data graph. 
Table B.109: Run 444, channel 5 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 12534 4.362E-05 66188 0.007776 65730000 42.93 28.27
Error (abs) 66.4 9.543E-07 935.6 9.91E-05 82070000 53.73 0.03707
Error (%) 0.530 2.188 1.414 1.274 124.859 125.157 0.131
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Run 460, channel 5: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 0.5 
µm. RSSE is 4.641. 
 
Figure B.110: Run 460, channel 5 model and data graph. 
Table B.110: Run 460, channel 5 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 1934 0.000149 8771 0.01146 6521000 20.62 31.56
Error (abs) 23.61 8.688E-06 365.4 0.00042 90400000 284.6 0.08816
Error (%) 1.221 5.831 4.166 3.668 1386.290 1380.213 0.279
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Run 464, channel 4: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 3.0 
µm. RSSE is 3.031. 
 
Figure B.111: Run 464, channel 4 model and data graph. 
Table B.111: Run 464, channel 4 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 280.8 0.0001939 1455 0.01857 3798 0.08797 61.42
Error (abs) 3.329 6.459E-06 228.1 0.001427 436.6 0.01876 0.4242
Error (%) 1.186 3.331 15.677 7.684 11.496 21.325 0.691
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Run 474, channel 5: Performed at pH 5.0 in sodium acetate, at an IgG concentration of 
1.0667 µm. RSSE is 4.299. 
 
Figure B.112: Run 474, channel 5 model and data graph. 
Table B.112: Run 474, channel 5 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 353000 0.1968 12781 6.88E-05 36303 0.005663 30.07
Error (abs) 34533 0.02008 66.19 1.05E-06 686.5 8.77E-05 0.04156
Error (%) 9.783 10.203 0.518 1.518 1.891 1.548 0.138
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Run 479, channel 5: Performed at pH 5.5 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 3.717. 
 
Figure B.113: Run 479, channel 5 model and data graph. 
Table B.113: Run 479, channel 5 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 3876000 3.517 7375 3.32E-05 28271 0.006998 25.42
Error (abs) 1748000 1.585 38.81 1.08E-06 538.6 0.000107 0.04253
Error (%) 45.098 45.067 0.526 3.242 1.905 1.535 0.167
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Run 485, channel 5: Performed at pH 5.5 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 3.555. 
 
Figure B.114: Run 485, channel 5 model and data graph. 
Table B.114: Run 485, channel 5 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 8.99E+08 815 12187 0.000142 34904 0.006144 27.73
Error (abs) 4.16E+10 37650 63.59 1.04E-06 502.2 0.0001 0.0431
Error (%) 4620.774 4619.632 0.522 0.732 1.439 1.629 0.155
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Run 490, channel 5: Performed at pH 5.5 in sodium acetate, at an IgG concentration of 1.067 
µm. RSSE is 2.565. 
 
Figure B.115: Run 490, channel 5 model and data graph. 
Table B.115: Run 490, channel 5 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 9.55E+08 663.5 10572 5.18E-05 30184 0.006241 22.45
Error (abs) 4.73E+10 32858 41.27 7.75E-07 426.4 7.49E-05 0.0261
Error (%) 4952.870 4952.223 0.390 1.497 1.413 1.199 0.116
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Run 495, channel 5: Performed at pH 5.5 in sodium acetate, at an IgG concentration of 0.5 
µm. RSSE is 4.89. 
 
Figure B.116: Run 495, channel 5 model and data graph. 
Table B.116: Run 495, channel 5 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 1.54E+09 340.1 22018 1.49E-05 46780 0.005938 30.33
Error (abs) 8.75E+10 19382 394.8 1.37E-05 1613 0.000289 0.07012
Error (%) 5702.932 5698.912 1.793 92.024 3.448 4.869 0.231
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Run 506, channel 5: Performed at pH 5.5 in sodium acetate, at an IgG concentration of 3.0 
µm. RSSE is 4.082. 
 
Figure B.117: Run 506, channel 5 model and data graph. 
Table B.117: Run 506, channel 5 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 8.16E+08 742.4 7313 9.1E-05 20900 0.005986 30.89
Error (abs) 7.9E+09 7194 40.07 9.16E-07 340.7 8.88E-05 0.03569
Error (%) 968.861 969.019 0.548 1.007 1.630 1.484 0.116
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Run 520, channel 5: Performed at pH 6.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 3.737. 
 
Figure B.118: Run 520, channel 5 model and data graph. 
Table B.118: Run 520, channel 5 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 8.71E+08 768.8 8558 8.72E-05 27383 0.01015 23.03
Error (abs) 5.53E+10 48797 52.84 1.07E-06 1003 0.00029 0.04464
Error (%) 6347.986 6347.164 0.617 1.226 3.663 2.859 0.194
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Run 530, channel 5: Performed at pH 6.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 3.156. 
 
Figure B.119: Run 530, channel 5 model and data graph. 
Table B.119: Run 530, channel 5 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 7.25E+08 601.5 6775 0.000106 17742 0.006777 35.09
Error (abs) 1.97E+09 1630 30.8 7.6E-07 284 9.56E-05 0.04258
Error (%) 271.023 270.989 0.455 0.719 1.601 1.411 0.121
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Run 535, channel 5: Performed at pH 6.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 4.593. 
 
Figure B.120: Run 535, channel 5 model and data graph. 
Table B.120: Run 535, channel 5 model parameters. 
 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 7.37E+08 476.7 8814 1.18E-05 18251 0.006969 30.69
Error (abs) 1.22E+10 7888 58.62 8.94E-07 597.1 0.000188 0.05334
Error (%) 1654.003 1654.709 0.665 7.587 3.272 2.695 0.174
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Run 540, channel 5: Performed at pH 6.0 in PBST, at an IgG concentration of 3.0 µm. RSSE 
is 2.321. 
 
Figure B.121: Run 540, channel 5 model and data graph. 
Table B.121: Run 540, channel 5 model parameters. 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 3.97E+08 358.1 7663 7.33E-05 17346 0.005331 29.01
Error (abs) 2.25E+09 2030 25.46 5.97E-07 191.1 5.27E-05 0.02308
Error (%) 566.675 566.881 0.332 0.815 1.102 0.989 0.080
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Run 545, channel 5: Performed at pH 6.0 in PBST, at an IgG concentration of 3.0 µm. RSSE 
is 5.901. 
 
Figure B.122: Run 545, channel 5 model and data graph. 
Table B.122: Run 545, channel 5 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 6.98E+09 8193 5180 0.000119 31191 0.01634 36.48
Error (abs) 1.5E+12 1758000 34.62 1.15E-06 1439 0.000524 0.07068
Error (%) 21461.3 21457.342 0.668 0.962 4.614 3.204 0.194
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Run 554, channel 5: Performed at pH 6.5 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 3.074. 
 
Figure B.123: Run 554, channel 5 model and data graph. 
Table B.123: Run 554, channel 5 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 9E+09 5827 16177 7.87E-05 27394 0.006485 24.93
Error (abs) 3.02E+13 19530000 79.44 7.46E-07 737.9 0.00014 0.02922
Error (%) 335073.3 335163.89 0.491 0.948 2.694 2.163 0.117
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Run 559, channel 5: Performed at pH 6.5 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 3.832. 
 
Figure B.124: Run 559, channel 5 model and data graph. 
Table B.124: Run 559, channel 5 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 1.14E+10 4425 12312 0.000104 39421 0.00823 33.56
Error (abs) 1.35E+12 523400 58.68 8.11E-07 840.4 0.000142 0.03929
Error (%) 11836.6 11828.249 0.477 0.782 2.132 1.727 0.117
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Run 574, channel 5: Performed at pH 6.5 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 3.299. 
 
Figure B.125: Run 574, channel 5 model and data graph. 
Table B.125: Run 574, channel 5 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 1.22E+10 3379 8927 0.000116 17386 0.006143 33.96
Error (abs) 5.67E+12 1565000 59.51 1.11E-06 539.2 0.00014 0.06427
Error (%) 46320.5 46315.478 0.667 0.958 3.101 2.281 0.189
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Run 579, channel 4: Performed at pH 6.5 in PBST, at an IgG concentration of 3.0 µm. RSSE 
is 3.11. 
 
Figure B.126: Run 579, channel 4 model and data graph. 
Table B.126: Run 579, channel 4 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 2.07E+09 12408 626.5 0.000338 1726 0.00996 35.96
Error (abs) 2.62E+12 15710000 7.04 5.73E-06 74.42 0.000357 0.1509
Error (%) 126544.4 126611.86 1.124 1.695 4.312 3.581 0.420
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Run 598, channel 5: Performed at pH 7.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 3.17. 
 
Figure B.127: Run 598, channel 5 model and data graph. 
Table B.127: Run 598, channel 5 model parameters. 
 
 
  
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 2553 4.652E-05 5331 0.000127 17242 0.007461 26.93
Error (abs) 186200 0.002667 186100 0.001548 306.5 0.000189 0.03731
Error (%) 7293.4 5733.0181 3490.902 1221.784 1.778 2.536 0.139
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Run 603, channel 5: Performed at pH 7.0 in PBST, at an IgG concentration of 1.067 µm. 
RSSE is 1.765. 
 
Figure B.128: Run 603, channel 5 model and data graph. 
Table B.128: Run 603, channel 5 model parameters. 
 
 
 
kfwd1 krev1 kfwd2 krev2 kfwd3 krev3 ProA (RU)
Value 5539 0 5297 0.000401 31555 0.01451 20.39
Error (abs) 6886 0.0001882 6783 0.000371 664.9 0.000413 0.02231
Error (%) 124.3 128.054 92.377 2.107 2.849 0.109
